




(86) Date de dépôt PCT/PCT Filing Date: 2017/05/31
(87) Date publication PCT/PCT Publication Date: 2017/12/07
(45) Date de délivrance/Issue Date: 2021/08/03
(85) Entrée phase nationale/National Entry: 2019/04/18
(86) N° demande PCT/PCT Application No.: US 2017/035328
(87) N° publication PCT/PCT Publication No.: 2017/210371
(30) Priorité/Priority: 2016/05/31 (US62/392,399)

(51) Cl.Int./Int.Cl. *C07C 217/58* (2006.01),
A61K 31/4412 (2006.01), *C07D 213/63* (2006.01)
(72) Inventeurs/Inventors:
CASHMAN, JOHN R., US;
RYAN, DANIEL J., US;
OKOLOTOWICZ, KARL, US
(73) Propriétaire/Owner:
HUMAN BIOMOLECULAR RESEARCH INSTITUTE, US
(74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : COMPOSES UTILISES COMME INHIBITEURS DES CANAUX SODIQUES

(54) Title: COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS



(57) Abrégé/Abstract:

Methods and small molecule compounds for inhibition of sodium channels are provided. One example of a class of compounds that may be used is represented by the compound of Formula (I) or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, R, R₁, R₁', R₂, R₃, R₄, R₅, R₆, R₇, R₈ are as described herein.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 December 2017 (07.12.2017)



(10) International Publication Number
WO 2017/210371 A3

(51) International Patent Classification:

C07C 217/58 (2006.01) A61K 31/4412 (2006.01)
C07D 213/63 (2006.01)

(21) International Application Number:

PCT/US2017/035328

(22) International Filing Date:

31 May 2017 (31.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/392,399 31 May 2016 (31.05.2016) US

(71) Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTE [CA/US]; 5310 Eastgate Mall, San Diego, CA 92121-2804 (US).

(72) Inventors: CASHMAN, John, R.; 5130 Eastgate Mall, Sandiego, CA 92121-2804 (US). RYAN, Daniel, J.; 5130 Eastgate Mall, San Diego, CA 92121-2804 (US). OKOLO-TOWICZ, Karl; 5130 Eastgate Mall, San Diego, CA 92121-2804 (US).

(74) Agent: CASTELLINO, Angelo; 16619 Larch Way, Apt. L105, Lynnwood, WA 98037 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,

MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

25 January 2018 (25.01.2018)

(54) Title: COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS

(57) Abstract: Methods and small molecule compounds for inhibition of sodium channels are provided. One example of a class of compounds that may be used is represented by the compound of Formula (I) or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, R, R₁, R'₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ are as described herein.




FIGURE 1

WO 2017/210371 A3

COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS

GRANT INFORMATION

[0100] This invention was not made with Federal government support.

FIELD OF THE DISCLOSURE

[0101] The disclosure relates generally to small molecule compounds and more specifically to derivatives of stereochemically defined phenoxy propan-2 amines and deuterated analogs for their use in cardiovascular and central nervous system diseases.

BACKGROUND OF THE DISCLOSURE

[0102] Cardiovascular disease is a leading cause of deaths in the United States. For example, heart attacks are the leading cause of death in men and women in the United States during 2010 with a total economic impact of \$40 B/year. 50% of individuals over the age of 65 suffering heart attacks die within 5 years of a heart attack. Despite this prevalence, options are limited. Treating arrhythmia in individuals before or after heart attacks and arrhythmia with Long QT (LQT) prolongation is also an unmet need. Thus, there is a major unmet medical need for the development of selective and inexpensive targeted treatments for cardiovascular disease.

[0103] The blockade of voltage gated sodium channels that inhibits the generation and propagation of an action potential is the mechanism that local anesthetics, antiarrhythmics and anticonvulsants prevent pathological firing of action potentials in excitable tissues. For example, Mexiletine, a well-established orally effective antiarrhythmic drug of the IB class is effective in treatment of muscular hyperexcitability of myotonic syndromes including ones with abnormal membrane excitability and delayed muscle relaxation after voluntary contraction. Sodium channel myotonias, paramyotonia congenital and hyperkaliemic periodic paralysis and epilepsy are among many diseases related to sodium channel mutations. The therapeutic effect of Mexiletine is directly associated with its ability to block voltage-dependent sodium channels present in cardiac and skeletal muscle fibers. Use-dependent blockers of sodium channels stabilize the channels in the inactivated state and allows a greater potency on tissues characterized by excessive excitability including myotonic muscles with

non-physiological phenotypes of sodium or chloride channels. The on and off rate of binding to the sodium channel determines the efficacy of the drug as well as the relative degree of toxicity. If the molecule binds too long, this interferes with sodium channel excitability. For Mexiletine, the potency of blocking the sodium channel can be correlated to lipophilicity of the molecule. The sodium channel target of Mexiletine that has a center of chirality has shown moderate or low stereoselectivity.

[0104] Mexiletine has shown clinical utility to decrease abnormal sodium channel discharges in myotonic syndromes. Mexiletine is the leading agent to treat cardiovascular disease in dogs. Despite the promise, Mexiletine has significant drawbacks. For example, the dose used for anti-myotonic effects are as great as those for exerting antiarrhythmic effects and can induce or worsen conduction defects. In addition, at the relatively elevated doses and multiple administrations due to its clearance required for therapeutic action, Mexiletine can have side effects on the central nervous system. Electrophysiological and biochemical evidence points to block of sodium channels in the central nervous system. For example, local anesthetics inhibits batrachotoxin A 20- α -benzoate and alters stereoselective binding of cocaine to sodium channels in the brain. After administration to animals, Mexiletine causes seizures and nausea. Thus, because the recommended dose to treat arrhythmia and myotonic patients are in the same range, adverse effects on both the cardiac and central nervous system are possible. Selective stimulation of different sodium channels may have utility for CNS diseases or seizures. In addition to effects on sodium channels, Mexiletine and other related drugs possess off-target effects on the potassium channel.

[0105] Despite the fact Mexiletine is a very old drug, little work has been done to re-engineer Mexiletine to remove side effects. For example, Class Ic anti-arrhythmics were examined in the CAST and CAST II studies. The results showed that treating patients with Class Ic sodium channel blockers post MI decreased arrhythmia in the short term, but led to greater instances of arrhythmia-related deaths in the long term. Class Ic anti-arrhythmics were chosen because other anti-arrhythmics (i.e., Class Ia and Ibs including Mexiletine) had been shown to not suppress arrhythmia or had adverse effects that precluded their use. In the current clinical setting sodium channel blockers are not used for the treatment of arrhythmia.

[0106] What is needed is a more potent compound with greater potency against on-target sites and less potency against off-target sites. For example, a desirable improvement on

Mexiletine would be to optimize the use dependence and the refractory period effect or decrease the inhibition of potassium (hERG) channel effects. The basis for effecting this could be changing the 3D structure or introducing new pharmaceutical properties. Until our work, no phenotypic cell-based assay was available to discern these effects. Arrhythmogenic agents can be identified in normal and LQT3 human patient-derived cardiomyocytes using a voltage-sensitive kinetic imaging cytometry assay. A phenotypic screen in human cardiomyocytes provided powerful information to ascertain on-target and off-target effects in highly relevant human cells. Important metrics of compound efficacy and safety were obtained including: action potential delay (APD) shortening (i.e., IC_{50} for on-target effects), APD prolongation (i.e., IC_{50} for off-target effects), early after depolarizations (EADs that provide evidence of arrhythmogenicity) and cessation of beating (i.e., a marker of acute arrhythmogenicity/toxicity). Concurrent evaluation of these metrics underscores the value of this approach using a whole-cell physiological approach. Results from our work provided several new compounds that showed significantly less arrhythmogenicity than Mexiletine in normal and LQT3 patient-derived cardiomyocytes. Compounds evaluated by electrophysiology confirmed and extended the results. Together, these data showed that chemical modifications to different portions of the parent Mexiletine decreased arrhythmogenic liability while modifications elsewhere affected on- and off-target effects. For example, unexpected selectivity on sodium and potassium channel inhibition by Mexiletine analogs was observed due to novel substituents. Also, unanticipated decrease in metabolism was observed by moving certain substituents or deuteration of Mexiletine likely due to unexpected changes in regioselective metabolism or structural aspects.

[0107] Mexiletine is relatively rapidly metabolized by hepatic enzymes and is relatively rapidly cleared in vivo. Multiple doses of Mexiletine are required for human efficacy because of metabolism, clearance and toxicity. Replacement of metabolically labile C-H bonds with metabolically less labile groups containing C-Cl or C-F or C-D or C-CF₃ or C-aryl or C-cyclopropyl groups afforded more bioavailable compounds. Compounds were chemically ($t_{1/2}$ > 30 days) and metabolically (hepatic microsomes + NADPH) stable (human $t_{1/2}$, > 60 min). In contrast to Mexiletine, select compounds showed no acute toxicity in mice *in vivo*. In a (24 hour) toxicity study, compounds administered to mice (100 or 200 mg/kg, i.p.) did not produce seizures. In contrast, Mexiletine-treated animals (100 or 200 mg/kg, i.p.) showed death, seizures and other behavior issues., The LD₅₀ for Mexiletine (114 mg/kg, i.p.) in mice shows


the therapeutic window is narrow. In contrast, analogs were non-toxic and well-tolerated *in vivo*.

[0108] Compounds described herein are drug-like small molecules and have characteristics that make them very attractive small molecules drugs. For example, analogs formulated as salts have excellent aqueous solubility and improved bioavailability, are chemically and metabolically stable and are non-toxic and highly potent and selective sodium channel inhibitors.

SUMMARY OF THE DISCLOSURE

[0109] In one aspect, the disclosure provides a nontoxic compound of Formula I or stereoisomers or a pharmaceutically acceptable salt, N-oxide or solvate capable of selectively inhibiting sodium channels:

[0110] A compound of Formula I:



[0111] or a stereoisomer, tautomer, isotope, or salt or thereof,

[0112] wherein:

[0113] A, B, D are independently Carbon or Nitrogen;

[0114] R₁ is selected from the group consisting of hydrogen, deuterium, methyl, trideuteromethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₆-C₂₄)aryl, and (C₅-C₂₄)heteroaryl, wherein (C₆-C₂₄)aryl and (C₆-C₂₄)heteroaryl are optionally substituted with 1 to 5 R₈ substituents independently selected from the group consisting of deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro, and (C₁-C₆)alkylsulfonyl;

[0115] R₂ is selected from the group consisting of hydrogen, deuterium, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₃-C₆)cycloheteroalkyl, 2-(C₁-C₆)alkoxyethyl, 2-hydroxyethyl, 2-(C₆-C₂₄)aryloxyethyl, bis(2-methoxyethyl), (C₁-C₆)alkoxymethyl, 2-(C₃-C₆)cycloalkoxyethyl, (C₆-C₂₄)aryl, and (C₆-C₂₄)heteroaryl, wherein (C₆-C₂₄)aryl and (C₆-C₂₄)heteroaryl are optionally substituted with 1 to 5 R₈ substituents selected from the group consisting of deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro and (C₁-C₆)alkylsulfonyl;

[0116] R₃ is absent if A is Nitrogen, or if A is Carbon R₃ is selected from the group consisting of hydrogen, deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro, and (C₁-C₆)alkylsulfonyl;

[0117] R₄ is absent if B is Nitrogen, or if B is Carbon R₄ is selected from the group consisting of hydrogen, deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro, and (C₁-C₆)alkylsulfonyl;

[0118] R₅ is absent if D is Nitrogen, or if D is Carbon R₅ is a substituent selected from the group consisting of hydrogen, deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro, and (C₁-C₆)alkylsulfonyl;

[0119] R₆ and R₇ are independently selected from the group consisting of hydrogen, deuterium, halo, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyloxy, (C₃-C₆)cycloalkyloxy, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₆-C₂₄)aryl amino, cyano, nitro, and (C₁-C₆)alkylsulfonyl.

[0120] R₁ is independently substituted *S* and/or *R* isomeric forms and/or racemic forms and can also be substituted with a deuterium at the center of chirality.

[0121] In another aspect the disclosure provides methods for stereoselectively synthesizing compounds inhibiting sodium channels, comprising contacting cells with a aryloxy propan-2-amine-based compound of Formula I in the form of a free base or a pharmaceutically acceptable salt, prodrug, hydrate, solvate or N-oxide thereof, wherein A, B, D, R, R₁-R₆, are as described above.

[0122] In another aspect the disclosure provides methods for stereoselectively inhibiting sodium channels, comprising contacting cells with a aryloxy propan-2-amine-based compound of Formula I in the form of a free base or a pharmaceutically acceptable salt, prodrug, hydrate, solvate or N-oxide thereof, wherein A, B, D, R, R₁-R₆, are as described above.

BRIEF DESCRIPTION OF THE DRAWINGS

[0123] **Figure 1.** Initiation of Early After Depolarization-Mediated Ectopic Ventricular Beats and Ventricular Fibrillation in an Isolated Perfused Aged Rat Heart Exposed to hydrogen peroxide. Simultaneous microelectrode (top) and pseudoECG are shown at baseline, 6 min & 12 min after exposure to H₂O₂. Notice the emergence of early afterdepolarization (EAD) & ectopic ventricular beats 6 min after exposure that degenerates to VT and VF after 12 min.

[0124] **Figure 2.** Complete resolution of all forms of arrhythmias to normal sinus rhythm 30 min after perfusion of Compound (R)-82 (10 uM) in an Isolated Perfused Aged Heart in the presence of hydrogen peroxide. Same preparation as in Figure 1 thirty min after perfusion with Compound (R)-82. Normal sinus rhythm is fully restored.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0125] The following terms, definitions and abbreviations apply. Abbreviations used herein have their conventional meaning within the chemical and biological arts.

[0126] The term “lipophilic” refers to moieties having an affinity for lipids and other fat-like substances, tending to combine with, and capable of dissolving, them.

[0127] The term “sodium channels” refers to voltage-dependent sodium channels in cells.

[0128] The term “mutant sodium channels” refers to variant sodium channels in cells with traits associated with abnormal or pathophysiologic behavior.

[0129] The term “myotonia” refers to a condition of cellular hyperexcitability and abnormal membrane excitability and delayed muscle relaxation after voluntary contraction, where the cells have lost specific structural, functional, and biochemical cell-cycle checkpoints.

[0130] The term "patient" refers to organisms to be treated by the methods of the disclosure. Such organisms include, but are not limited to humans or other animals. In the context of the disclosure, the term "subject" generally refers to an individual who will receive or who has received treatment described below (e.g., administration of the compounds of the disclosure, and optionally one or more additional therapeutic agents).

[0131] Where substituent groups are specified by their conventional chemical formula, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., $--CH_2O--$ is equivalent to $--OCH_2--$.

[0132] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., C_1-C_{10} means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclopropyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl, and the higher homologs and isomers. Alkyl groups which are limited to hydrocarbon groups are termed "homoalkyl".

[0133] The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkyl, as exemplified, but not limited, by $--CH_2CH_2CH_2CH_2--$, $--CH_2CH=CHCH_2--$, $--CH_2CCCH_2--$, $--CH_2CH_2CH(CH_2CH_2CH_3)CH_2--$. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of at least one carbon atoms and at least one heteroatom selected from the group consisting of O, N, P, Si and S, and wherein the nitrogen, phosphorus, and sulfur atoms

may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N, P and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, --CH₂--CH₂--O--CH₃, --CH₂--CH₂--NH--CH₃, --CH₂--CH₂--N(CH₃)--CH₃, --CH₂--S--CH₂--CH₃, --CH₂--CH₂, --S(O)--CH₃, --CH₂--CH₂--S(O)₂--CH₃, --CH=CH--O--CH₃, --Si(CH₃)₃, --CH₂--CH=N--O CH₃, --CH=CH--N(CH₃)--CH₃, O--CH₃, --O--CH₂--CH₃, and --CN. Up to two or three heteroatoms may be consecutive, such as, for example, --CH₂--NH--O CH₃ and --CH₂--O--Si(CH₃)₃. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, --CH₂--CH₂--S--CH₂--CH₂--and --CH₂--S--CH₂--CH₂--NH--CH₂--. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxo, alkylenedioxo, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula --C(O)OR'--represents both --C(O)OR'--and --R'OC(O)--. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as --C(O)R', --C(O)NR', --NR'R", --OR', --SR, and/or --SO₂R'. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as --NR'R" or the like, it will be understood that the terms heteroalkyl and --NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as --NR'R" or the like.

[0134] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclopropyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. The

terms "cycloalkylene" and "heterocycloalkylene" refer to the divalent derivatives of cycloalkyl and heterocycloalkyl, respectively.

[0135] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C₁-C₄)alkyl" is meant to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0136] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings, which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms (in each separate ring in the case of multiple rings) selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxaliny, 5-quinoxaliny, 3-quinolyl, and 6-quinolyl. Substituents for each of above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. The terms "arylene" and "heteroarylene" refer to the divalent radicals of aryl and heteroaryl, respectively.

[0137] For brevity, the term "aryl" when used in combination with other terms (e.g., aryloxy, arylthio, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like). However, the term "haloaryl," as used herein is meant to cover only aryls substituted with one or more halogens.


[0138] Where a heteroalkyl, heterocycloalkyl, or heteroaryl includes a specific number of members (e.g., "3 to 7 membered"), the term "member" refers to a carbon or heteroatom.

[0139] The term "oxo or keto" as used herein means an oxygen that is double bonded to a carbon atom.

[0140] The terms "heterocycle" and "heterocyclic" refer to a monovalent unsaturated group having a single ring or multiple condensed rings, from 1 to 8 carbon atoms and from 1 to 4 heteroatoms, for example, nitrogen, sulfur or oxygen within the ring.

[0141] The term "methylthio" refers to a moiety $-S-CH_3$. Sulfonyl refers to S-oxide.

[0142] The term "sulfonamide" refers to compound A shown below, as well as to the other



A

moieties derived from compound A: The terms "furyl," "tetrahydrofuryl," and "pyridyl" refer to radicals formed by removing one hydrogen from the molecules of furan, tetrahydrofuran, and pyridine, respectively.

[0144] The terms "alkyl amine" and "cyclic amine" refer to alkanes or cycloalkanes, respectively, having one hydrogen substituted by a primary, secondary or tertiary amino group, as well as to the moieties and radicals derived from such amines.

[0145] The term "alkyl amide" refers to alkanes, having one hydrogen substituted by a primary, secondary or tertiary amino group.

[0146] Each of above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," and "heterocycloalkyl," "aryl," "heteroaryl" as well as their divalent radical derivatives) are meant to include both substituted and unsubstituted forms of the indicated radical.

[0147] Substituents for alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl monovalent and divalent derivative radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: $-OR'$, $=O$, $=NR'$, $=N-OR'$, $-NR'R''$, $-SR'$, -halogen, $-SiR'R''R'''$, $-OC(O)R'$, $-C(O)R'$, $-CO_2R'$, $-C(O)NR'R''$, $-OC(O)NR'R''$, $-NR''C(O)R'$, $-NR'-C(O)NR''R'''$, $-NR''C(O)OR'$, $-NR- C(NR'R'')=NR'''$, $-S(O)R'$, $-S(O)_2R'$, $-S(O)_2NR'R''$, $-NR' SO_2R'$, $-CN$ and $-NO_2$ in a

number ranging from zero to $(2m'+1)$, where m' is the total number of carbon atoms in such radical. R' , R'' , R''' and R'''' each independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the disclosure includes more than one R group, for example, each of the R groups is independently selected as are each R' , R'' , R''' and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, $--NR'R''$ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., $--CF_3$ and $--CH_2CF_3$) and acyl (e.g., $--C(O)CH_3$, $--C(O)CF_3$, $--C(O)CH_2OCH_3$, and the like).

[0148] The term "alkoxy" refers to the moiety $--O-alkyl$, wherein alkyl is as defined above. Examples of alkoxy structures that are within the purview of the definition include, but are not limited to, (C_1-C_6) alkoxy radicals, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, *sec*-butoxy, *tert*-butoxy, pentoxy, 3-pentoxy, or hexyloxy.

[0149] Similar to the substituents described for alkyl radicals above, exemplary substituents for aryl and heteroaryl groups (as well as their divalent derivatives) are varied and are selected from, for example: halogen, $--OR'$, $--NR'R''$, $--SR'$, -halogen, $--SiR'R''R'''$, $--OC(O)R'$, $--C(O)R'$, $--CO_2R'$, $--C(O)NR'R''$, $--OC(O)NR'R''$, $--NR'C(O)R'$, $--NR'--C(O)NR''R'''$, $--NR''C(O)OR'$, $--NR--C(NR'R''R''')=NR''''$, $--NR--C(NR'R'')=NR'''$, $--S(O)R'$, $--S(O)_2R'$, $--S(O)_2NR'R''$, $--NRSO_2R'$, $--CN$ and $--NO_2$, $--R'$, $--N_3$, $--CH(Ph)_2$, fluoro (C_1-C_4) alkoxo, and fluoro (C_1-C_4) alkyl, in a number ranging from zero to the total number of open valences on aromatic ring system; and where R' , R'' , R''' and R'''' are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the disclosure includes more than one R group, for example, each of the R groups is independently selected as are each R' , R'' , R''' and R'''' groups when more than one of these groups is present.

[0150] Two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally form a ring of the formula $-T-C(O)-(CRR')_q-U-$, wherein T and U are independently $--NR--$, $--O--$, $--CRR'--$ or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula $-A-(CH_2)_r-B-$, wherein A and B are independently $--CRR'--$, $--O--$, $--NR--$, $--S--$, $--S(O)--$, $--S(O)_2--$, $--S(O)_2NR'--$ or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of aryl or heteroaryl ring may optionally be replaced with a substituent of the formula $-(CRR')_s-X'-(C''R''')_d-$, where s and d are independently integers of from 0 to 3, and X' is $--O--$, $--NR'--$, $--S--$, $--S(O)--$, $--S(O)_2--$, or $--S(O)_2NR'--$. The substituents R, R', R'' and R''' are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0151] As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), or silicon (Si).

[0152] An "aminoalkyl" as used herein refers to an amino group covalently bound to an alkylene linker. The amino group is $--NR'R''$, wherein R' and R'' are typically selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0153] A "substituent group," as used herein, means a group selected from the following moieties: (A) $--OH$, $--NH_2$, $--SH$, $--CN$, $--CF_3$, $--NO_2$, $--S(O)-alkyl$, $--S(O)-aryl$, $--S(O_2)-alkyl$, $S(O_2)-aryl$, oxo, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from: (i) oxo, $--OH$, $--NH_2$, $--SH$, $--CN$, $--CF_3$, $--NO_2$, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from: (a) oxo, $--OH$, $--NH_2$, $--SH$, $--CN$, $--CF_3$, $--NO_2$, halogen, unsubstituted alkyl,

unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted with at least one substituent selected from oxo, --OH, --NH₂, --SH, --CN, --CF₃, --NO₂, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl.

[0154] A "size-limited substituent" or "size-limited substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C₁-C₂₀ alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C₄-C₈ cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 4 to 8 membered heterocycloalkyl.

[0155] A "lower substituent" or "lower substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C₁-C₈ alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C₅-C₇ cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.

[0156] In the examples, we categorized the effects of **1** on biological assays as follows: +++++, IC₅₀ 0 – 10 μM; +++, IC₅₀ 10 – 50 μM; ++, IC₅₀ 50 – 100 μM; +, IC₅₀ > 100 μM; NR, no response.

[0157] The compounds of the disclosure may exist as salts. Examples of applicable salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures, succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art. Also included are base addition salts such as sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When the disclosed compounds contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such

compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, *p*-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like. Certain specific compounds of the disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0158] The term "pharmaceutically acceptable salts" is meant to include salts of active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituent moieties found on the compounds described herein. When compounds of the disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, *p*-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the disclosure contain

both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0159] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0160] Certain compounds of the disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the disclosure. Certain compounds of the disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by and are intended to be within the scope of the disclosure.

[0161] Certain compounds of the disclosure possess centers of chirality (e.g., asymmetric carbon atoms), optical or chiral centers or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (*R*)- or (*S*)- or, as (*D*)- or (*L*)- for amino acids, and individual isomers are encompassed within the scope of the disclosure. The compounds of the disclosure do not include those which are known in art to be too unstable to synthesize and/or isolate. The disclosure is meant to include compounds in racemic and optically pure forms. Optically active (*R*)- and (*S*)-, or (*D*)- and (*L*)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers.

[0162] The term "tautomer," as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. It will be apparent to one skilled in the art that certain compounds of the disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.

[0163] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the *R* and *S* configurations for each center of chirality

(e.g., an asymmetric carbon center). Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.

[0164] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C - or ^{14}C -enriched carbon are within the scope of the disclosure.

[0165] The compounds of the disclosure may also contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotope, such as for example, tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the disclosure, whether radioactive or not, are encompassed within the scope of the disclosure. Nonradioactive isotopes include deuterium (^2H), carbon-13 (^{13}C) and nitrogen-15 (^{15}N).

[0166] In addition to salt forms, the disclosure provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical or metabolism-mediated changes under physiological conditions to provide the compounds of the disclosure. For example, a phosphate or other ester moiety or other prodrug moiety may be independently attached to $\text{R}_1\text{-R}_6$). Additionally, prodrugs can be converted to the compounds of the disclosure by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

[0167] The terms "a," "an," or "a(n)", when used in reference to a group of substituents herein, mean at least one. For example, where a compound is substituted with "an" alkyl or aryl, the compound is optionally substituted with at least one alkyl and/or at least one aryl. Moreover, where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different.

[0168] Description of compounds of the disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.

[0169] The terms "treating" or "treatment" in reference to a particular disease includes prevention of the disease.

[0170] The disclosure also provides articles of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of disorders and wherein said pharmaceutical composition comprises a compound according to the disclosure.

[0171] The disclosure also provides pharmaceutical compositions comprising at least one compound in an amount effective for treating a disorder, and a pharmaceutically acceptable vehicle or diluent. The compositions of the disclosure may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

[0172] The compounds of the disclosure may be formulated into therapeutic compositions as natural or salt forms. Pharmaceutically acceptable non-toxic salts include the base addition salts (formed with free carboxyl or other anionic groups) which may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, procaine, and the like. Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as, for example,

hydrochloric, sulfuric, or phosphoric acids, or organic acids such as acetic, citric, *p*-toluenesulfonic, methanesulfonic acid, oxalic, tartaric, mandelic, and the like. Salts of the disclosure include amine salts formed by the protonation of an amino group with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like. Salts of the disclosure may also include amine salts formed by the protonation of an amino group with suitable organic acids, such as *p*-toluenesulfonic acid, acetic acid, and the like. Additional excipients which are contemplated for use in the practice of the disclosure are those available to those of ordinary skill in the art, for example, those found in the United States Pharmacopeia Vol. XXII and National Formulary Vol. XVII, U.S. Pharmacopeia Convention, Inc., Rockville, Md. (1989).

In addition, polymorphs, hydrates, and solvates of the compounds are included in the disclosure.

[0173] The disclosed pharmaceutical compositions may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, intrathecal, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The present compounds may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds may also be administered liposomally or with cavitands (i.e., Captisol).

[0174] In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the disclosure. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).

[0175] The term "therapeutically effective amount" means the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, e.g., restoration or maintenance of vasculostasis or prevention of the compromise or loss of vasculostasis; reduction of tumor burden; reduction of morbidity and/or mortality.

[0176] By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0177] The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the disclosure or pharmaceutical composition to the subject in need of treatment. The term "contacting" should be understood to mean providing a compound of the disclosure or pharmaceutical composition either in vitro or in vivo.

[0178] The pharmaceutical compositions for the administration of the compounds of this embodiment either alone or in combination with other agents, may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of disease. The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.

[0179] Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic

pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.

[0180] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0181] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. Also useful as a solubilizer is polyethylene glycol, for example. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, *p*-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0182] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil

such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0183] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0184] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

[0185] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally-acceptable diluent or solvent or cosolvent or complexing agent or dispersing agent or excipient or combination thereof, for example 1,3-butane diol, polyethylene glycols, polypropylene glycols, ethanol or other alcohols, povidones, Tweens, sodium dodecyle sulfate, sodium deoxycholate, dimethylacetamide, polysorbates, poloxamers, cyclodextrins, e.g., sulfobutyl ether β -cyclodextrin, Captisol, lipids, and excipients such as inorganic salts (e.g., sodium chloride), buffering agents (e.g., sodium citrate, sodium phosphate), and sugars (e.g., saccharose and dextrose). Among the acceptable vehicles and solvents that may be employed are water, dextrose solutions, Ringer's solutions and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0186] Depending on the condition being treated, these pharmaceutical compositions may be formulated and administered systemically or locally. Suitable routes may, for example, include oral or transmucosal administration; as well as parenteral delivery, including

intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. For injection, the pharmaceutical compositions of the disclosure may be formulated in aqueous solutions, for example, in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. For tissue or cellular administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0187] The compounds of the disclosure may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the disclosure are employed. For purposes of this application, topical application shall include mouthwashes and gargles.

[0188] In the methods described herein, an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. The dosage level can be about 0.01 to about 250 mg/kg per day, such as 0.01 to about 100 mg/kg per day, for example, 0.01 to about 10 mg/kg per day, such as 0.04 to about 5 mg/kg per day, or about 0.5 to about 100 mg/kg per day. A suitable dosage level may be also about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day or 1.0 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day for example. The Examples section shows that one of the exemplary compounds was dosed at 30 mg/kg/day and also at about 100 mg/kg/day. For oral administration, the compositions may be provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0,

10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, or once or twice per day. There may be a period of no administration followed by another regimen of administration. Administration of the compounds may be closely associated with the schedule of a second agent of administration.

[0189] It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, gender, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0190] Thus, in one embodiment the disclosure provides a compound of Formula I or stereoisomers or a pharmaceutically acceptable salt, prodrugs, N-oxide or solvate capable of inhibiting sodium channels:

Formula I

[0191] A, B, D are independently Carbon, Nitrogen, R, R₁, R₂, R₃, R₄, R₅ = H, deuterium, alkyl, aryl, halo, O-alkyl, O-aryl, N-alkyl, N,N-dialkyl, N-aryl, N,N-diaryl, S-, S-aryl, S(O)-alkyl, S(O)-aryl, S(O₂)-alkyl, S(O₂)-aryl, cycloalkyl, cycloheteroalkyl, heteroaryl.

[0192] R is independently substituted hydrogen, deuterium, trideuteromethyl, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, O-alkyl, N-alkyl, O-aryl, -(CH₂)₁₋₆OH, -(CH₂)₁₋₆SH, -(CH₂)₁₋₆NH₂, -(CH₂)₁₋₆OR₁₁, -(CH₂)₁₋₆SR₁₁, -(CH₂)₁₋₆N(R₁₁)₂, where R₁₁ is independently substituted hydrogen, (C₁-C₆)alkyl, aryl, CF₃, C₂F₅, hydroxyl, O-alkyl, O-aryl, cycloalkyl(C₁-C₆), alkyl(C₁-C₆)amine, alkyl cyclic(C₁-C₆)amine, alkyl(C₁-C₆) N,N-dialkylamino, alkyl (C₁-C₆)aryl amine, cycloheteroalkyl, heteroaryl, methylcycloalkyl(C₁-C₆), methylaryl, methylcycloheteroalkyl, methylheteroaryl, methylcyclopropyl, or a moiety forming a salt; or unsubstituted phenyl, substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 independently substituted; or a moiety forming a salt;

[0193] R_1 is independently substituted hydrogen, deuterium, trideuteromethyl, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, O-alkyl, N-alkyl O-aryl, -(CH₂)₁₋₆OH, -(CH₂)₁₋₆SH, -(CH₂)₁₋₆NH₂, -(CH₂)₁₋₆OR₁₁, -(CH₂)₁₋₆SR₁₁, -(CH₂)₁₋₆N(R₁₁)₂, where R_{11} is independently substituted hydrogen, (C₁-C₆)alkyl, aryl, CF₃, C₂F₅, hydroxyl, O-alkyl, O-aryl, cycloalkyl(C₁-C₆), alkyl(C₁-C₆)amine, alkyl cyclic(C₁-C₆)amine, alkyl(C₁-C₆) N,N-dialkylamino, alkyl (C₁-C₆)aryl amine, cycloheteroalkyl, heteroaryl, methylcycloalkyl(C₁-C₆), methylaryl, methylcycloheteroalkyl, methylheteroaryl, methylcyclopropyl, or a moiety forming a salt; or unsubstituted phenyl, substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 independently substituted; or a moiety forming a salt;

[0194] R_2 is independently substituted hydrogen, deuterium, trideuteromethyl, O, O₂, (C₁-C₆)alkyl, aryl, CF₃, C₂F₅, hydroxyl, O-alkyl, O-aryl, cycloalkyl(C₁-C₆), alkyl(C₁-C₆)amine, alkyl cyclic(C₁-C₆)amine, alkyl(C₁-C₆) N,N-dialkylamino, alkyl (C₁-C₆)aryl amine, cycloheteroalkyl, heteroaryl, methylcycloalkyl(C₁-C₆), methylaryl, methylcycloheteroalkyl, methylheteroaryl, methylcyclopropyl, or a moiety forming a salt; or unsubstituted phenyl, substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 independently substituted;

[0195] R_3 is independently substituted hydrogen, deuterium, trideuteromethyl, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, O-alkyl, O-aryl, S-alkyl, S-aryl, amine, cyclic amine, aryl amine or a moiety forming a salt;

[0196] R_4 is independently substituted hydrogen, deuterium, trideuteromethyl, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, O-alkyl, O-aryl, S-alkyl, S-aryl, S(O)-alkyl, S(O)-aryl, S(O₂)-alkyl, S(O₂)-aryl, amine, cyclic amine, aryl amine or a moiety forming a salt;

[0197] R_5 is independently substituted hydrogen, deuterium, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, hydroxyl, O-alkyl, O-aryl, S-alkyl, S-aryl, S(O)-alkyl, S(O)-aryl, S(O₂)-alkyl, S(O₂)-aryl, cycloalkyl(C₁-C₆), alkyl(C₁-C₆)amine, alkyl cyclic(C₁-C₆)amine, alkyl(C₁-C₆) N,N-dialkylamino, alkyl (C₁-C₆)aryl amine, cycloheteroalkyl, heteroaryl, methylcycloalkyl(C₁-C₆), methylaryl, methylcycloheteroalkyl, methylheteroaryl, methylcyclopropyl, or a moiety forming a salt; or unsubstituted phenyl, substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 independent substitutes, O-alkyl, O-aryl, amino, N-alkylamino, N-aryl amino, or hydroxyl or amino prodrug moieties;

[0198] R_6 is independently substituted hydrogen, deuterium, trideuteromethyl, (C₁-C₆)alkyl, aryl, halogen, CF₃, C₂F₅, O-alkyl, N-alkyl O-aryl, -(CH₂)₁₋₆OH, -(CH₂)₁₋₆SH, -(CH₂)₁₋₆NH₂, -(CH₂)₁₋₆OR₁₁, -(CH₂)₁₋₆SR₁₁, -(CH₂)₁₋₆N(R₁₁)₂, where R₁₁ is independently substituted hydrogen, (C₁-C₆)alkyl, aryl, CF₃, C₂F₅, hydroxyl, O-alkyl, O-aryl, cycloalkyl(C₁-C₆), alkyl(C₁-C₆)amine, alkyl cyclic(C₁-C₆)amine, alkyl(C₁-C₆) N,N-dialkylamino, alkyl (C₁-C₆)aryl amine, cycloheteroalkyl, heteroaryl, methylcycloalkyl(C₁-C₆), methylaryl, methylcycloheteroalkyl, methylheteroaryl, methylcyclopropyl, or a moiety forming a salt; or unsubstituted phenyl, substituted or unsubstituted pyridine, wherein phenyl or pyridine is optionally independently substituted with 1 to 3 independently substituted; or a moiety forming a salt;

[0199] R is independently substituted *S* and/or *R* isomeric forms and/or racemic forms,

[0200] In another aspect the disclosure provides methods for stereoselectively synthesizing compounds inhibiting sodium channels, comprising contacting cells with a aryloxy propan-2-amine-based compound of Formula I in the form of a free base or a pharmaceutically acceptable salt, prodrug, hydrate, solvate or N-oxide thereof, wherein A, B, D, R, R₁-R₆, are as described above.

[0201] In another aspect the disclosure provides methods for stereoselectively inhibiting sodium channels, comprising contacting cells with a aryloxy propan-2-amine-based compound of Formula I in the form of a free base or a pharmaceutically acceptable salt, prodrug, hydrate, solvate or N-oxide thereof, wherein A, B, D, R, R₁-R₆, are as described above.

[0202] R is independently substituted as the R isomeric form

[0203] R is independently substituted *S* and/or *R* isomeric forms and/or racemic forms,

[0204] In another aspect the disclosure provides compounds of Formula I wherein the pharmaceutically acceptable salt is the salt of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid (L), aspartic acid (L), benzenesulfonic acid, benzoic acid, camphoric acid (+), camphor-10-sulfonic acid (+), capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid

(D), gluconic acid (D), glucuronic acid (D), glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid (DL), lactobionic acid, lauric acid, maleic acid, malic acid (- L), malonic acid, mandelic acid (DL), methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyroglutamic acid (- L), salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid (+ L), thiocyanic acid, toluenesulfonic acid (p), or undecylenic acid

EXAMPLES

[0205] The embodiments of the disclosure may be further illustrated by the following non-limiting examples.

EXAMPLE 1: KINETICS FOR APD IN CARDIOMYOCYTES





[0206] Data (i.e., IC50 values) from experiments with normal human induced pluripotent stem cell (hiPSC) cardiomyocyte or cardiomyocytes derived from hiPSCs from a LQTS3 patient (cells obtained from CDI International) were obtained from dose escalation experiments using a high throughput membrane potential assay using the novel voltage sensitive dye, VF2.1 Cl. Normal or LQTS3 patient-derived cardiomyocytes were cultured for 2 weeks prior to imaging. On the day of the experiment, the cells were washed with Tyrode's solution and each compound was added to the cells from a 2x stock, incubated for 5 minutes and imaged for 6.5 seconds at 100Hz using a kinetic imaging cytometer (KIC) (Vala Sciences) to obtain fluorescence versus concentration effects. Subsequent image analysis and physiological parameter calculations was conducted using Cyteseer software from Vala Sciences. Dose response curves were generated using Graphpad Prism software. Maturity of sodium, potassium and calcium channels were fully characterized in both normal and LQT3 cardiomyocytes with single cell patch clamp voltage-gated studies. This data was compared to data obtained from channels transfected into cells (see Example 2).









[0207] Normal cardiomyocytes dose response. A plot of log of action potential delay (APD)₇₅ vs. log of racemic Mexiletine or Mexiletine analogs concentration in molar dose response curve for a dose escalation of Mexiletine in normal hiPSC derived cardiomyocytes









afforded prolongation of 2.85 fold (n=5) (Table 1, below). The plot showed the dose dependent prolongation of the action potential duration in response to Mexiletine.







[0208] LQTS3 dose response-log: A plot of log of APD75 vs. log of racemic Mexiletine concentration in molar dose response curve for a dose escalation of Mexiletine in LQTS3 patient- derived cardiomyocytes afforded an IC₅₀ value of 1.83 uM for shortening APD and 1.34-fold shortening (n = 5) (Table 2, below). The plot showed a dose dependent shortening of the action potential duration for a dose escalation of Mexiletine. The data showed the utility of using normal human and patient-derived cardiomyocytes to afford molecules with superior on-target vs. off-target effects. Mexiletine analogs were likewise tested. This identified optimal compounds that shortened the APD.







[0209] **Table 1. Pharmacological Parameters in Normal human IPSC-derived Cardiomyocytes.**






No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
1		183	22	8.3	54	2.5	3.4	200	2.653	66	
2a		128	30	4.3	54	1.8	2.4	200	2.661	133	
2b		129	19	6.8	84	4.4	1.5	200	2.289	200	
9		162	52	3.1	98	1.9	1.7	200	2.363	200	







No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
10		130	7.3	18.0	30	4.1	4.3	66	2.262	22	
11		124	36	3.4	44	1.2	2.8	22	2.194	22	
12		91	11	8.3	49	4.5	1.9	7.4	>4	22	
13		21	12	1.8	8	0.7	2.6		1.389	22	
14									None	None	None
15									None	None	66
16									None	None	66
17									None	None	66








No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
18	• HCl 								None	None	None
19	• HCl 								None	None	133
20	NH ₂ • HCl 								None	None	None
21	OH • HCl 	128.6	21.2	6.1	100	4.7	1.3		None	None	None
22	CH ₃ OH • HCl 	Not Done									
23	NH ₂ • HCl 								None	None	22
24	NH ₂ • HCl 								None	None	66
25	NH ₂ • HCl 	34.2	0.642	53.3	22.9	35.7	1.5		None	None	133









No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
26								7.4	2.502	7.4	22
27		41.1	1.04	39.5	37.5	36.1	1.1		None	None	66
28									None	None	66
29									None	None	None
30									None	None	133
31									None	None	None







No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
32									None	None	133
33									None	None	133
34									None	None	133
35									None	None	133
36		25.8	0.747	34.5	27.6	36.9	0.9		None	None	None
37									None	None	None









No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
38								66	4.584	66	200
39								66	3.827	22	133
40								66	4.366	32	None
41								133	5.338	32	None
42									1.684	5.7	200








No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
43									None	None	None
44								22	2.698	2.5	133
45									None	None	None
46									None	None	None
47									Not Determined		
48									None	None	None

No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
49									1.385	7.8	200
50									1.392	23.5	None
51									None	None	None
52								133	2.499	97.7	None
53									None	None	None
54									None	None	66
55		154	17	9.1	49	2.9	3.1		1.159	22	None







No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
56								133	3.925	133	None
57								200	3.615	133	None
58								200	2.392	133	None
59								133	2.832	22	None
60								66	2.805	22	200
61								66	3.829	66	None
62								66	1.585	66	200
63								66	1.577	66	None



No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
64								133	2.621	66	None
65								66	2.12	66	200
66		22.1	2.1	10.5	5.9	2.8	3.7		None	None	66
67		135.6	10.6	12.8	63	5.9	2.2	66	2.408	66	None
68								66	1.686	66	200
69		38.3	0.845	45.3	5.1	6.0	7.5		None	None	200




No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
70		18.9	0.182	103	6.2	34.0	3.0		None	None	66
71								200	1.997	200	None
72								133	2.93	200	None
73									None	None	66
74								133	2.633	133	None
75									None	None	66
76									None	None	66
77									None	None	66







No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
78		20	1.03	19.4					None	None	133
79								200	5.06	133	None
80		45.1	1.02	44.2	16.8	16.5	2.7		None	None	None
81									None	None	66
82		44.3	1.14	38.9					None	None	66
83									None	None	133
84									None	None	133






No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
85									None	None	200
86								66	1.68	66	None
87									None	None	None
88									1.52	66	None
89		24.3	1.6	15.2	4.9	3.1	5.0				
90		33.4	2.83	11.8					None	None	133
91		76.8	10	7.7	45.8	4.6	1.7				
92									None	None	66





No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
93									None	None	66
94								133	2.48	133	None
95								133	2.68	200	None
96									1.163	200	None
97								133	None	None	None
98									1.54	7.4	





No. Code	Structure	Peak Na ⁺ (I _{NaP}) IC ₅₀ (uM)	Late Na ⁺ (I _{NaL}) IC ₅₀ (uM)	D _{NaP} / NaL	hER G (I _{Kr}) IC ₅₀ (uM)	D _{Kr} / NaL	D _{NaP} / Kr	WT- EAD Dose (uM)	WT-Fold Prolongation	WT- Prolonga tion Dose (uM)	Cessation of Beating (uM)
99											
100	 • HCl	252	n/a	n/a	n/a	n/a	n/a		None	None	None





No. Code	Structure	LQT-IC ₅₀ (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
1	 • HCl	1.83	None		1.335	22
2a	 • HCl	0.96	None		1.346	7.4
2b	 • HCl	0.8	None		1.25	22





No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
9		0.76	None		1.28	22
10		0.8	200		1.162	22
11		1.48	133		1.112	22
12		0.648	22		1.182	2.5
13		0.72	66		1.174	2.5
14		None	None		None	None





No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
15			66		1.42	7.4
16		1.38	66		1.480	22
17			66		1.58	22
18			None		None	None
19		1.38	133		1.406	66





No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
20			None		None	None
21			None		1.23	7.4
22			None		1.29	133
23		0.78	22		1.32	2.5





No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
24		0.38	22		1.979	7.4
25		0.73	66		1.606	22
26		0.13	133		1.482	0.8
27		>0.8	66		1.783	22






No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
28		>0.8	66		1.620	22
29		>0.8	None		1.64	66
30		20.16	200		1.423	133
31			133		None	None






No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
32		7.53	66		1.355	22
33			22		None	None
34			66		1.29	22
35			66		1.406	22






No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
36		5.73	200		1.508	133
37			None		None	None
38			200		1.19	2.5
39		0.73	66		1.180	2.5






No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
40		2.31	None		1.267	7.4
41			None		None	None
42			133		1.26	22
43			None		None	None






No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
44			7.4		1.7	2.5
45			None		1.37	133
46			None		1.67	133
47			Not done		-	-







No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
48	 • HCl		None		None	None
49	 • HCl	0.85	133		1.192	7.4
50	 • HCl	6.01	None		1.12	22
51	 • HCl		None		1.37	133
52	 • HCl		None		None	None







No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
53			None		None	None
54		57.82	133		1.45	66
55		4.45	200		1.232	66
56		0.04	None		1.189	7.4
57		0.19	None		1.14	7.4








No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
58			None		None	None
59			None		None	None
60		0.11	200		1.22	0.8
61			200		None	None
62		1.03	200		1.19	22







No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
63		7.5	200		1.11	22
64			None		None	None
65		1.36	200		1.119	66
66		0.486	66		1.192	7.4
67		None	None		None	None




No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
68		0.022	200		1.11	66
69		None	200		None	None
70		0.0013	66		1.279	7.4
71		193.7 (prolongation)	None		1.214 (prolongation)	200
72		128.9 (prolongation)	None		1.133 (prolongation)	200

No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
73		0.082	66		1.136	0.8
74			None		None	None
75			66		1.370	22
76			66		1.244	22
77			200		1.18	22
78		23.08	66		1.208	22

No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
79			None		1.145	133
80		6.59	133		1.636	66
81		4.07	66		1.539	22
82		20.56	66		1.442	22
83		0.0023	66		1.410	22
84		0.87	66		1.200	7.4

No. Code	Structure	LQT-IC50 (uM)- Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
85		31.34	200		1.661	133
86		Shortens	None		1.418	200
87		34.78	None		1.611	133
88		12.82	None		1.287	66
89						
90			133		1.1	22
91						

No. Code	Structure	LQT-IC50 (uM)-Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
92			66		1.41	22
93			22		1.5	7.4
94			None		None	None
95			22		1.22	22
96			None		1.3	133
97			None		1.1	22






No. Code	Structure	LQT-IC50 (uM)-Shortening	LQT-Cessation Dose (uM)	LQT-EAD Dose (uM)	LQT-Fold Shortening	LQT-Shortening Dose (uM)
98			66		1.3	22
99			22		1.49	7.4
100			22		1.13	7.4

EXAMPLE 2. ELECTROPHYSIOLOGY




[0210] INa and IKr assays (n = 6) were run by patch clamp electrophysiology and confirmed the in vitro potency observed with the Kinetic Image Cytometer (KIC) assays. This provided data to investigate the physiology and action of target compounds on individual ion channels. The assay used standardized protocols for culturing and conducting conventional whole cell recording that have been previously developed for both current and voltage-clamp to characterize action potentials using transfected cells. Briefly, the Nav1.5 sodium channel was transfected into HEK293 cells. The cells were validated using standard assays previously developed and further validated using dose response studies that afforded IC50 values. hERG was expressed in CHO cells and used in automated patch clamp assays. Briefly, cells were plated on 0.1% gelatin-coated 35-mm plastic Petri dishes. Conventional whole cell recording

conditions were used in both current and voltage-clamp to characterize action potentials in these cells to investigate the physiology and pharmacology of individual ion channels and the effect of Mexiletine or Mexiletine analogs on function. Data was reported as IC_{50} values $\pm$ STD (Table 1). For example, racemic Mexiletine had NaI channel Peak (INaP) IC_{50} = 183 μ M, NaI channel Late (INaL) IC_{50} = 22 μ M (ratio = 8.3) and hERG potassium channel (IKr) IC_{50} = 54 μ M. Compound 70 had a Na Peak IC_{50} = 18.9 μ M, Na Late IC_{50} = 0.18 μ M (ratio = 104) and hERG IC_{50} = 6 μ M. Analog 70 was thus much more selective for the on-target Na Late channel than Mexiletine.

Table 1. Electrophysiology Results for Mexiletine and Analogs using Transfected Cells.

Compound	Structure	Results					
		Peak Na ⁺ (INaP) IC_{50} (μ M)	Late Na ⁺ (INaL) IC_{50} (μ M)	D _{NaP} / NaL	hERG (IKr) IC_{50} (μ M)	D _{Kr} /NaL	D _{NaP} /Kr
Rac Mexiletine, 1		182.8	22.5	8.3	54	2.5	73
36		25.8	0.747	34.5	27.6	36.9	0.93
70		20.1	0.2	100.5	6.2	34.0	3.0
91		76.8	10.0	7.68	45.8	4.6	1.7
21		128.6	21.2	6.1	>100	>4.7	1.3
69		38.0	0.753	50.5	5.1	6.8	7.5


67		135.6	10.6	12.8	63.0	5.9	2.2
25		34.2	0.642	53.2	22.9	35.6	1.5
82		41.1	1.04	39.5	37.5	36.1	1.1
89		24.3	1.6	15.3	4.9	3.1	5.0
66		22.1	2.1	10.7	5.9	2.8	3.7
78		20.0	1.03	19.4	7.2	7.0	2.77
80		45.1	1.02	44.2	16.8	16.5	2.7
88		90.9	1.04	87.4	11.2	10.7	7.7

105		44.3	1.14	38.9	20.9	18.3	2.11
90		33.4	2.83	11.8	25.3	1.32	1.32
35		10.9	1.03	10.6	9.2	8.9	1.2

[0211] Patch clamp recordings from hiPSC LQT3 patient-derived cardiomyocytes for Na⁺ channel currents were recorded in response to computed voltage waveforms that simulated adult ventricular action potentials. These channels were recorded in human cardiomyocytes and showed all the relevant ion channels in a native context. This confirmed the KIC data that revealed a compound's on- and off-target effects. Patch-clamp recording of hiPSC-LQT3 patient-derived cardiomyocytes showed the presence of functional K⁺, Na⁺ and Ca²⁺ currents, typical for functional cardiomyocytes. Patch clamp studies with LQT3 patient-derived cardiomyocytes showed a significantly prolonged Na⁺ current, reflecting the substantial proportion of late Na⁺ current component. The NaI channel Peak (INaP) IC₅₀ >100 μM, NaI channel Late (INaL) IC₅₀ = 1.8 μM (ratio >56) for 82. The NaI channel Peak (INaP) IC₅₀ >100 μM, NaI channel Late (INaL) IC₅₀ = 1.74 μM (ratio > 57) for 25. The results are in good agreement with previous electrophysiology data (Table 1, above) and that obtained from optical screening assays (KIC assays). The results showed more potent and selective sodium channel inhibitors with more favorable (lower) potassium channel inhibition were obtained.


EXAMPLE 3: SYNTHESIS OF COMPOUNDS OF FORMULA I-

[0212] The phenoxy propan-2-amine-based compounds of general structure I:



[0213] (I),

[0214] was synthesized according to the following Schemes:



Scheme 1: General Synthetic Procedure for synthesis of aryloxy propan-2-amines of compound **I**.

[0215] Potassium carbonate (1.5 eq.) was added to a stirred solution of 2,6-dimethylphenol (1.5 eq.) and bromoacetone (0.5 M, 1.0 eq.) in DMF at 21 °C. After 12-24 hours, the mixture was poured into water and extracted with diethyl ether (2x), washed with 2N NaOH_(aq) (5x), dried (Na₂SO₄), filtered, and concentrated. The product was purified by silica gel column chromatography (ethyl acetate/hexanes) to provide alpha-aryloxy ketones.

[0216] The synthesis of Mexiletine enantiomers was done as follows. A two-step condensation-reduction protocol was used to convert ketones **5** to *N*-tert-butanesulfinyl amines **7** without isolation of hydrolytically unstable *N*-tert-butanesulfinyl imines (i.e., **6**). Reduction of **6** showed substrate and reagent-based stereoselectivity wherein sodium borohydride and L-selectride favored opposite diastereomers of **7**. Product diastereomer ratios of **7** were

determined by RP HPLC analysis of the crude product. Following separation of diastereomers **7** by silica gel chromatography, (*R_C*, *R_S*-**7**) and (*S_C*, *R_S*-**7**) were separately treated with 4N HCl in 1,4-dioxane. The products (*R*)-**8** and (*S*)-**8** were obtained as hydrochloride salts and the enantiopurity of the products was determined by chiral phase HPLC. Isolated products were obtained in greater than 95% purity as judged by ¹H NMR or HPLC-UV/MS analysis. For **1-3** that have not been experimentally characterized in the scientific literature, the (*R_C*) and (*S_C*) designations of **7** were assumed based on their optical rotation data and HPLC chromatographic profile compared to close structural analogs.


[0217] General Procedure "A" for Synthesis of N-tert-butanesulfinyl Amines 5-10. Ti(OEt)₄ (2.2 eq.) was added to a mixture of ketone (1.0 eq.) and (R)-tert-butanesulfinamide (1.2 eq.) in a glass microwave vial, sealed and the neat mixture was subjected to microwave heating at 70 °C for 1h, cooled, diluted with EtOAc and added to a saturated solution of NaCl(aq) (0.1 mL/mmol Ti(OEt)₄) with stirring. The resulting suspension was vacuum-filtered through Celite, concentrated and dissolved in THF (1.7 mL/mmol ketone) and CuSO₄ (1.0 eq.) and NaBH₄ (1.2 eq.) were added at 21 °C. After 5 h, acetic acid was added, stirred for 5 min, and concentrated and re-suspended in CH₂Cl₂, vacuum-filtered through Celite and concentrated. Products were analyzed by HPLC to determine diastereomeric ratio, then purified by silica gel flash column chromatography as described below. Product purity was determined by HPLC to be >95 % in all examples. See Example 4, below, for examples.

[0218] General Procedure "B" for Synthesis of N-tert-butanesulfinyl Amines. The method is the same as A, above, but the concentrate was dissolved in THF (1.7 mL/mmol ketone) and cooled to -45 °C. L-Selectride (1.2 eq., 1 M solution in THF) was added at -45 °C. After 5 h, acetic acid was added. The mixture was removed from the cold, stirred for 5 min, concentrated by rotary evaporation, re-suspended in CH₂Cl₂, vacuum-filtered through Celite and the filtrate was concentrated. Products were analyzed by HPLC to determine diastereomeric ratio and purified by silica gel flash column chromatography as described for individual products below. Product purity was determined by HPLC to be >95 % in all examples. See Example 5 for purity analysis.

[0219] General Procedure for Removal of the N-tert-butanesulfinyl Group. N-tert-butanesulfinyl amines (i.e., 5-10) were dissolved in 4 N HCl in 1,4-dioxane. After 5-12 hours, the mixture was diluted with diethyl ether (2 eq.) to effect precipitation of the product amine


hydrochloride salts. The suspension was vacuum-filtered and dried under high-vacuum to provide amine hydrochlorides as white solids. See Example 4 for examples.

[0220] Scheme 3. Synthetic approach to primary amines.



[0222] **General Procedure “C” for Amines from Oximes.** *O*-benzylhydroxylamine (1.42 mmol, 2.1 eq.) and pyridine (1.74 mmol, 1.4 eq.) were added to a solution of 1-(aryloxy)propan-2-one (1.24 mmol, 1.0 eq.) in ethanol (12 mL) at 21 °C and the flask was immersed in a 45 °C oil bath. After 2 days, the mixture was concentrated, and the reaction concentrate was diluted with ethyl acetate and washed with water. The organic layer was dried (Na_2SO_4), filtered, and concentrated. The product was purified by silica gel flash column chromatography on a CombiFlash (0 to 70% ethyl acetate/hexanes) to provide oxime (1.14 mmol, >92% yield) as a pale yellow oil that was generally a 3.8:1.0 ratio of oxime isomers by ^1H NMR.

[0223] **Scheme 4.** Synthetic approach to *N*-substituted Mexiletine analogs and non-chiral analogs.




[0224] A, B, or D are
C or N atoms

General Procedure “D” for Amine Enantiomers from Diastereomers. See Example 4, **Scheme 1** for examples.


[0225] **Racemic 1.1-(2,6-dimethylphenoxy)-*N*-methylpropan-2-amine.** For **13**: $R_f = 0.23$ (10% methanol in dichloromethane); Commercially available.

[0226] **Scheme 2:** Synthetic Procedure for synthesis of cyclic amine intermediate **2** where F = nitrogen, A, B, D, E = carbon R, R1, R3, R4 = Hydrogen and R2 = methyl (Compound **2**, **Scheme 1**) a. DIEA, ACN reflux overnight; b. $\text{Na}_2\text{S}_2\text{O}_4$ K_2CO_3 EtOH/ H_2O 50 °C 2h; c. LAH THF reflux overnight.



[0227] **(R)-mexiletine HCl**


[0228] **Compound (R)-2a (R)-(-)-Mexiletine hydrochloride.** Prepared from **(R_C, R_S)-5** (60.7 mg, 0.213 mmol) using the general procedure provided **(R)-1** hydrochloride (80% yield). **(R)-1** had e.r. > 99:1 (*R:S*) using chiral HPLC method described below. **(R)-1** hydrochloride: (¹H NMR, ¹³C NMR, MS) in agreement with literature values. $[\alpha]_D^{20}$ -2.6 (*c* 0.62, CH₃OH); literature values $[\alpha]_D^{20}$ -2.9 (*c* 1.0, CH₃OH), $[\alpha]_D^{20}$ -2.4 (*c* 2.0, CH₃OH). ¹H NMR for **(R)-(-)-Mexiletine hydrochloride** (300 MHz, CDCl₃): δ 8.77 (b, 2H), 6.97 (m, 3H), 6.99-6.89 (m, 3H), 4.00-3.89 (AB of ABX, J_{AB} = 9.6 Hz, 2H), 3.79 (b, 1H), 2.32 (s, 6H), 1.64 (d, J = 6.6 Hz, 3H) ppm. ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 154.7, 130.9, 129.2, 124.7, 71.8, 48.5, 16.8, 15.8 ppm. LRMS (ESI-TOF) m/z calc. for C₁₁H₁₇NO [M+H⁺] 180.1; found 180.1.



[0229] **(S)-mexiletine HCl**


[0230] **Compound (S)-2b. (S)-(+)-Mexiletine hydrochloride.** Prepared from **(S_C, R_S)-5** using the procedure that provided **(S)-1** hydrochloride (79% yield). **(S)-1**: e.r. >99 (*S:R*) using chiral HPLC. **(S)-1** hydrochloride: (¹H NMR, ¹³C NMR, MS) in agreement with literature values and identical to **(R)-1** characterized above. $[\alpha]_D^{20}$ +2.1 (*c* 0.66, CH₃OH); literature values $[\alpha]_D^{20}$ +2.6 (*c* 1.0, CH₃OH), $[\alpha]_D^{20}$ +2.2 (*c* 2.0, CH₃OH).

[0231]




[0232] **Compound 9. 1-(2-Methylphenoxy)propan-2-amine**, was made following the general method, above (83% yield) as a pale yellow oil: R_f = 0.2 (15% MeOH/CH₂Cl₂):¹H NMR (300 MHz, CDCl₃) δ 7.16 (m, 2H, *H*Ar), 6.87 (td, J = 7.5, 1.1 Hz, 1H, *H*Ar), 6.82 (m, 1H, *H*Ar), 3.93-3.70 (AB of ABX, J_{AB} = 8.8 Hz, 2H, CH₂), 3.41 (m, 1H, CH), 2.27 (s, 3H,

CH_3), 1.23 (d, $J = 6.6$ Hz, 1H, CH_3) ppm. ESI/MS for $\text{C}_{10}\text{H}_{15}\text{NO}$: *calc.* $[\text{M}+\text{H}]^+ = 166.1$, *found* $m/z = 166.1$.



[0233]


[0234] **Compound (R)-10** (*R*)-1-cyclopropyl-2-(2,6-dimethylphenoxy)ethan-1-amine hydrochloride, [DAR-V-143] and [DAR-V-196]. Prepared from (*R*_C,*Ss*)-**5** as above (13% yield). (*R*)-**1** had e.r. >96 (*R*:*S*) using chiral HPLC. $[\alpha]_D^{20} -19$ (c 0.41, CH_3OH); LRMS (ESI-TOF) m/z calc for $\text{C}_{13}\text{H}_{19}\text{NO}$ $[\text{M}+\text{H}^+]$ 206.2; found 206.0.



[0235]


[0236] **Compound (S)-10** (*S*)-1-cyclopropyl-2-(2,6-dimethylphenoxy)ethan-1-amine hydrochloride. Prepared from (*S*_C, *Ss*)-**5** using the general procedure provided (*S*)-**1** hydrochloride (49% yield). (*S*)-**1** had e.r. > 96 (*R* : *S*) using chiral HPLC. $[\alpha]_D^{20} +30$ (c 0.36, CH_3OH); ^1H NMR (300 MHz, CDCl_3): δ 8.91 (b, 2H), 6.95 (m, 3H), 4.11 (m, 2H), 2.82 (m, 1H), 2.33 (s, 6H), 1.45 (m, 1H), 0.86 (m, 1H), 0.75 (m, 2H), 0.45 (m, 1H) ppm. LRMS (ESI-TOF) m/z calc for $\text{C}_{13}\text{H}_{19}\text{NO}$ $[\text{M}+\text{H}^+]$ 206.2; found 206.0.

[0237]




[0238] **Compound rac 10**. 1-cyclopropyl-2-(2,6-dimethylphenoxy)ethanamine, was made according to the general procedure above (85% yield) as a pale yellow oil/solid. $R_f = 0.17$ (10% $\text{MeOH}/\text{CH}_2\text{Cl}_2$); ^1H NMR (300 MHz, CDCl_3) δ 7.03–6.90 (m, 3H, *H*Ar), 3.90–3.77 (AB of ABX, $J_{AB} = 9.0$ Hz, 2H, CH_2), 2.41 (m, 1H, overlapping with neighboring peak, *CH*), 2.32 (s, 6H, 2 x CH_3), 0.96 (m, 1H, *CH*), 0.57 (m, 2H), 0.32 (m, 2H) ppm.

[0239]




[0240] **Compound 11. 1-(2,6-dimethylphenoxy)-N-methylpropan-2-amine**, [DAR-III-149] was made according to the general procedure above (38% yield) as a pale yellow oil/solid. $R_f = 0.23$ 10% MeOH/CH₂Cl₂: ¹H NMR (300 MHz, CDCl₃) δ 7.02 – 6.93 (m, 3H, *H*Ar), 6.43 (broad s, 1H), 3.93 (m, 2H, CH₂), 3.58 (m, 1H, CH), 2.86 (s, 3H, NCH₃), 2.30 (s, 6H, 2 x CH₃), 1.52 (d, $J = 6.6$ Hz, 3H, CH₃) ppm.




[0241]

[0242] **Compound 12. 1-(2,6-dimethylphenoxy)-3,3-dimethylbutan-2-amine**. ESI/MS: calculated C₁₄H₂₃NO $m/z = 221.2$, found $m/z = 222.0$ [M+H]. ¹H NMR (CDCl₃): 1.03 (s, 9H), 2.31 (s, 6H), 3.12 – 3.16 (m, 1H), 3.75 – 3.87 (m, 2H), 6.89 – 6.94 (m, 1H), 6.96 – 7.02 (m, 2H).




[0243]

[0244] **Compound (R)-13 (R)-(+)-2-(2,6-dimethylphenoxy)-1-phenylethanamine hydrochloride**. Prepared from (*S*_C, *R*_S)-**8** as above (78% yield). (¹H NMR, ¹³C NMR, HRMS) in agreement with literature values. $[\alpha]_D^{20} -4.0$ (c 0.63, MeOH); literature for (*S*)-enantiomer $[\alpha]_D^{20} +3.5$ (c 0.48, MeOH). ¹H NMR for (*R*)-(+)-2-(2,6-dimethylphenoxy)-1-phenylethanamine hydrochloride (300 MHz, CD₃OD): δ 7.56-7.44 (m, 5H), 7.01-6.89 (m, 3H), 4.78 (X of ABX, 1H), 4.16-4.04 (AB of ABX, $J_{AB} = 10.4$ Hz, 2H), 2.20 (s, 6H) ppm. ¹³C{¹H} NMR (125 MHz, CD₃OD): δ 155.6, 135.4, 131.4, 130.6, 130.3, 130.1, 128.5, 125.8, 72.9, 56.7, 16.2 ppm. HRMS (ESI-TOF) m/z calc for C₁₆H₁₉NO [M+Na⁺] 264.1364; found 264.137.




[0245]

Compound 14. 2-(2,6-dimethylphenoxy)-1-(4-methoxyphenyl)ethanamine. ESI/MS: m/z = $[M+H]^+$. ^1H NMR (CDCl_3): 2.26 (s, 6H), 3.79 – 3.82 (m, 2H), 3.80 (s, 3H), 4.39 – 4.43 (m, 1H), 6.85 – 6.92 (m, 3H), 6.97 – 6.99 (m, 2H), 7.36 (s, J = 8.8 Hz, 2H).




[0246]

Compound 15. 2-(2,6-dimethylphenoxy)-1-(4-methoxyphenyl)ethanamine. ESI/MS: m/z = $[M+H]^+$. ^1H NMR (CDCl_3): 2.26 (s, 6H), 3.79 – 3.82 (m, 2H), 3.80 (s, 3H), 4.39 – 4.43 (m, 1H), 6.85 – 6.92 (m, 3H), 6.97 – 6.99 (m, 2H), 7.36 (s, J = 8.8 Hz, 2H).



[0247]

Compound 16. 2-(2,6-dimethylphenoxy)-1-(4-(trifluoromethyl)phenyl)ethanamine. ESI/MS: m/z = $[M+H]^+$. ^1H NMR (CDCl_3): 2.23 (s, 6H), 3.78 – 3.88 (m, 2H), 4.51 (dd, J = 4.4 Hz and 4.4 Hz, 1H), 6.88 – 6.93 (m, 1H), 6.97 – 7.00 (m, 2H), 7.56 – 7.72 (m, 4H).




[0249]

Compound 17. 2-(2,6-dimethylphenoxy)-1-p-tolyethanamine.

ESI/MS: m/z = $[M+H]^+$. ^1H NMR (CDCl_3): 2.29 (s, 6H), 2.36 (s, 3H), 3.78 – 3.87 (m, 2H), 4.43 (dd, J = 4.1 Hz and 8.0 Hz, 1H), 6.88 – 6.93 (m, 1H), 6.98 – 7.01 (m, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H).

[0252] **Compound 18.** ^1H NMR (499 MHz, Chloroform-*d*) δ 4.70 (s, 2H), 5.38 (s, 2H), 6.24 (td, J = 1.3, 6.7 Hz, 1H), 6.62 (d, J = 9.1 Hz, 1H), 7.22 (dd, J = 2.1, 6.8 Hz, 1H), 7.27 – 7.43 (m, 6H), 7.52 (t, J = 7.8 Hz, 2H), 7.63 (td, J = 1.3, 7.4 Hz, 1H), 8.01 – 8.06 (m, 2H).

[0253] **Compound 19.** ^1H NMR (499 MHz, Chloroform-*d*) δ 2.16 (s, 3H), 4.70 (s, 2H), 5.35 (s, 2H), 6.17 (t, J = 6.7 Hz, 1H), 7.09 – 7.15 (m, 1H), 7.26 (s, 1H), 7.27 (dd, J = 1.1, 2.1 Hz, 0H), 7.28 – 7.40 (m, 5H), 7.51 (t, J = 7.8 Hz, 2H), 7.63 (dd, J = 1.2, 14.9 Hz, 0H), 7.63 (s, 1H), 8.01 – 8.07 (m, 2H).




[0254]

[0255] **Compound 20.** 1-phenyl-2-(pyridin-2-yloxy)ethanamine. ESI/MS: m/z = $[\text{M}+\text{H}]$. ^1H NMR (CDCl_3): 4.00 (dd, J = 7.1 Hz and 13.7 Hz, 1H), 4.44 (dd, J = 2.7 Hz and 13.7 Hz, 1H), 5.17 (dd, J = 2.7 Hz and 7.7 Hz, 1H), 6.12 (t, J = 6.6 Hz, 1H), 6.66 (d, J = 9.3 Hz, 1H), 7.05 (dd, J = 1.7 Hz and 6.6 Hz, 1H), 7.28 – 7.31 (m, 2H), 7.34 – 7.40 (m, 4H).


[0256] **Compound 21.** ^1H NMR (499 MHz, Chloroform-*d*) δ 2.19 (s, 3H), 4.02 (dd, J = 7.7, 13.7 Hz, 1H), 4.41 (dd, J = 2.7, 13.7 Hz, 1H), 5.17 (dd, J = 2.7, 7.7 Hz, 1H), 6.05 (t, J = 6.7 Hz, 1H), 6.94 (dd, J = 1.9, 6.8 Hz, 1H), 7.21 – 7.29 (m, 1H), 7.25 – 7.33 (m, 1H), 7.35 (dd, J = 6.7, 8.4 Hz, 2H), 7.36 – 7.43 (m, 2H).

[0257] **Compound 22.** ^1H NMR (300 MHz, Chloroform-*d*) δ 0.79 (s, 9H), 0.97 (s, 14H), 2.30 (s, 6H), 2.43 (s, 1H), 3.02 (dd, J = 2.8, 9.4 Hz, 1H), 3.62 (t, J = 9.1 Hz, 1H), 3.83 (s, 1H), 3.84 (dd, J = 2.8, 8.9 Hz, 1H), 6.86 – 7.06 (m, 3H).




[0258]

[0259] **Compound 23.** 1-phenyl-2-(2-propylphenoxy)ethanamine. ESI/MS: calc. $\text{C}_{17}\text{H}_{21}\text{NO}$ m/z = 255.2, found m/z = 256.0 $[\text{M}+1]^+$ ^1H NMR (CDCl_3): 0.95 (t, J = 7.4 Hz, 3H), 1.57 (sextet, J = 7.4 Hz, 2H), 2.36 (bs, 2H), 2.56 – 2.61 (m, 2H), 3.98 – 4.04 (m, 1H), 4.11 (dd, J = 4.4 Hz and 9.1 Hz, 1H), 4.44 – 4.48 (m, 1H), 6.77 – 6.80 (m, 1H), 6.84 – 6.90 (m, 1H), 7.08 – 7.14 (m, 2H), 7.29 – 7.38 (m, 4H), 7.44 – 7.47 (m, 1H).




[0260]

[0261] **Compound 24. 1-phenyl-2-(2-ethoxyphenoxy)ethanamine.** ESI/MS: calc. $C_{16}H_{19}NO$ m/z = 241.2, found m/z = 242.0 [M+1]. 1H NMR ($CDCl_3$): 1.18 (t, J = 7.4 Hz, 3H), 2.52 (bs, 2H), 2.65 (q, J = 7.4 Hz, 2H), 3.99 – 4.05 (m, 1H), 4.12 (dd, J = 4.1 Hz and 9.1 Hz, 1H), 4.45 – 4.49 (m, 1H), 6.77 – 6.80 (m, 1H), 6.86 – 6.91 (m, 1H), 7.08 – 7.15 (m, 2H), 7.29 – 7.38 (m, 4H), 7.44 – 7.47 (m, 1H).




[0262]

[0263] **Compound 25. 1-phenyl-2-(o-tolyloxy)ethanamine.** ESI/MS: calc. $C_{15}H_{17}NO$ m/z = 227.1, found m/z = 228.0 [M+1]. 1H NMR ($CDCl_3$): 2.24 (s, 3H), 2.88 (bs, 2H), 3.98 – 4.05 (m, 1H), 4.13 (dd, J = 4.1 Hz and 9.1 Hz, 1H), 4.45 – 4.49 (m, 1H), 6.75 – 6.78 (m, 1H), 6.83 – 6.88 (m, 1H), 7.08 – 7.13 (m, 2H), 7.29 – 7.37 (m, 4H), 7.44 – 7.47 (m, 1H).




[0264]

Compound 26. 2-(2-methoxyphenoxy)-1-phenylethanamine. ESI/MS: calc. $C_{15}H_{17}NO$ m/z = 243.1, found m/z = 244.0 [M+1]. 1H NMR ($CDCl_3$): 2.68 (bs, 2H), 3.79 (m, 3H), 4.05 – 4.11 (m, 1H), 4.15 – 4.20 (m, 1H), 4.48 – 4.52 (m, 1H), 6.86 – 6.98 (m, 4H), 7.30 – 7.39 (m, 4H), 7.47 – 7.50 (m, 1H).




[0265]

[0266] **Compound 27. 1-phenyl-2-(2-(trifluoromethyl)phenoxy)ethanamine.** ESI/MS: calc. $C_{15}H_{14}F_3NO$ $m/z = 281.1$, found $m/z = 282.0$ $[M+1]^+$ 1H NMR ($CDCl_3$): 2.38 (bs, 2H), 4.02 – 4.11 (m, 1H), 4.19 – 4.27 (m, 1H), 4.48 – 4.58 (m, 1H), 6.91 – 6.94 (m, 1H), 6.98 – 7.03 (m, 1H), 7.29 – 7.42 (m, 4H), 7.44 – 7.49 (m, 2H), 7.54 – 7.58 (m, 1H).




[0267]

[0268] **Compound 28. N-(2-(2,6-dimethylphenoxy)-1-phenylethyl)acetamide.** ESI/MS: calc. $C_{18}H_{21}NO_2$ $m/z = 283.2$, found $m/z = 284.0$ $[M+1]^+$ 1H NMR ($CDCl_3$): 2.11 (s, 6H), 3.98 – 4.10 (m, 2H), 5.33 – 5.39 (m, 1H), 6.39 – 6.43 (m, 1H), 6.87 – 6.98 (m, 3H) 7.29 – 7.43 (m, 4H).



[0269]


[0270] **Compound 29. N-(2-(2,6-dimethylphenoxy)-1-phenylethyl)benzamide.** ESI/MS: calc. $C_{23}H_{23}NO_2$ $m/z = 345.2$, found $m/z = 346.0$ $[M+1]^+$. 1H NMR ($CDCl_3$): 2.13 (s, 6H), 4.11 (dd, $J = 3.9$ Hz and 9.4 Hz, 1H), 4.21 (dd, $J = 4.4$ Hz and 9.4 Hz, 1H), 5.52 – 5.58 (m, 1H), 6.39 – 6.43 (m, 1H), 6.88 – 6.98 (m, 4H), 7.15 – 7.18 (m, 1H), 7.30 – 7.41 (m, 4H), 7.44 – 7.53 (m, 4H), 7.84 – 7.88 (1H).



[0271]


[0272] **Compound 30. 2-(2,3-dimethylphenoxy)-N-butyl-1-phenylethanamine** was made according to the general method above (66% yield) as a pale yellow oil that solidified over time. $R_f = 0.25$ (2% MeOH/ CH_2Cl_2) 7.49–7.46 (m, 2H, H_{Ar}), 7.41–7.29 (m, 3H, H_{Ar}),

7.02 (t, $J = 8.0$ Hz, 1H, *H*Ar), 6.79 (d, $J = 7.4$ Hz, 1H, *H*Ar), 6.67 (d, $J = 8.0$ Hz, 1H, *H*Ar), 4.17 (app dd, $J = 8.2, 3.9$ Hz, 1H, *CH*), 4.10-3.99 (m, 2H, *CH*₂), 2.59 (t, $J = 6.9$ Hz, 2H, *CH*₂), 2.30 (s, 3H, *CH*₃), 2.19 (s, 3H, *CH*₃), 1.54 (m, 2H, *CH*₂), 1.40 (m, 2H, *CH*₂), 0.94 (t, $J = 7.4$ Hz, 3H, *CH*₃) ppm.




[0100]

[0273] **Compound 31.** 2-(2,3-dimethylphenoxy)-*N*-propyl-1-phenylethanamine was made by the method above (66% yield) as a pale yellow oil that solidified over time. $R_f = 0.23$ (2% MeOH/*CH*₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 7.50–7.46 (m, 2H, *H*Ar), 7.42–7.29 (m, 3H, *H*Ar), 7.03 (t, $J = 7.7$ Hz, 1H, *H*Ar), 6.79 (d, $J = 7.1$ Hz, 1H, *H*Ar), 6.68 (d, $J = 8.0$ Hz, 1H, *H*Ar), 4.18 (app dd, $J = 8.5, 4.1$ Hz, 1H, *CH*), 4.10-3.99 (m, 2H, *CH*₂), 2.56 (t, $J = 7.1$ Hz, 2H, *CH*₂), 2.30 (s, 3H, *CH*₃), 2.19 (s, 3H, *CH*₃), 1.58 (m, 2H, *CH*₂), 0.96 (t, $J = 7.7$ Hz, 3H, *CH*₃) ppm.




[0274]

[0275] **Compound 32.** 2-(2,3-dimethylphenoxy)-1-phenylethanol, $R_f = 0.73$ (2% methanol in dichloromethane); ¹H NMR (300 MHz, CDCl₃) δ 7.50–7.46 (m, 2H, *H*Ar), 7.44–7.31 (m, 3H, *H*Ar), 7.04 (t, $J = 8.0$ Hz, 1H, *H*Ar), 6.82 (d, $J = 7.4$ Hz, 1H, *H*Ar), 6.69 (d, $J = 8.2$ Hz, 1H, *H*Ar), 5.17 (dd, $J = 8.5, 3.6$ Hz, 1H, *CH*), 4.15-4.00 (AB of ABX, $J_{AB} = 9.6$ Hz, 2H, *CH*₂), 2.31 (s, 3H, *CH*₃), 2.21 (s, 3H, *CH*₃) ppm.



[0276]

[0277] **Compound 33.** 2-(2,3-dimethylphenoxy)-*N*-ethyl-1-phenylethanamine, was made according to the general procedure above (97% yield) as a pale yellow oil that solidified over time. *R*_f = 0.18 (4% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 7.49–7.46 (m, 2H, *H*Ar), 7.41–7.29 (m, 3H, *H*Ar), 7.01 (t, *J* = 8.0 Hz, 1H, *H*Ar), 6.78 (d, *J* = 7.4 Hz, 1H, *H*Ar), 6.68 (d, *J* = 8.3 Hz, 1H, *H*Ar), 4.20 (app dd, *J* = 8.0, 4.7 Hz, 1H, *CH*), 4.12–4.03 (m, 2H, *CH*₂), 2.64 (q, *J* = 7.2 Hz, 2H, *CH*₂), 2.29 (s, 3H, *CH*₃), 2.17 (s, 3H, *CH*₃), 1.17 (t, *J* = 7.1 Hz, 3H, *CH*₃) ppm.




[0278]

[0279] **Compound 34.** 2-(2,3-dimethylphenoxy)-*N*-methyl-1-phenylethanamine, was prepared by the general method above (97% yield) as a pale yellow oil that solidified over time. *R*_f = 0.33 (5% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 7.48–7.46 (m, 2H, *H*Ar), 7.42–7.3 (m, 3H, *H*Ar), 7.01 (t, *J* = 7.7 Hz, 1H, *H*Ar), 6.78 (d, *J* = 7.4 Hz, 1H, *H*Ar), 6.68 (d, *J* = 8.3 Hz, 1H, *H*Ar), 4.02 (m, 3H, *CH*, *CH*₂), 2.42 (s, 3H, *NCH*₃), 2.29 (s, 3H, *CH*₃), 2.18 (s, 3H, *CH*₃) ppm.

[0280] **Compound 35.** 2-(2,3-dimethylphenoxy)-1-phenylethanamine, was made according to the above procedure (58% yield) as a pale yellow oil that solidified over time. *R*_f = 0.27 (5% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 7.5–7.47 (m, 2H, *H*Ar), 7.42–7.28 (m, 3H, *H*Ar), 7.03 (t, *J* = 7.7 Hz, 1H, *H*Ar), 6.79 (d, *J* = 7.5 Hz, 1H, *H*Ar), 6.68 (d, *J* = 8.0 Hz, 1H, *H*Ar), 4.47 (dd, *J* = 7.7, 3.8 Hz, 1H, *CH*), 4.13–3.95 (AB of ABX, *J*_{AB} = 9.1 Hz, 2H, *CH*₂), 2.39 (broad s, 2H, *NH*₂), 2.30 (s, 3H, *CH*₃), 2.19 (s, 3H, *CH*₃) ppm.

[0281] **Compound 36.** 2-(2,3-dimethylphenoxy)-*N*-methoxy-ethyl-1-phenylethanamine, ¹H NMR (300 MHz, Chloroform-*d*) δ 1.27 (d, *J* = 6.5 Hz, 7H), 2.29 (s, 6H), 3.58 – 3.79 (m, 2H), 4.14 – 4.31 (m, 1H), 6.92 (dd, *J* = 6.2, 8.4 Hz, 1H), 6.96 – 7.05 (m, 2H), 7.25 (s, 1H).


[0282] **Compound 37.** ¹H NMR (300 MHz, Chloroform-*d*) δ 0.98 (t, *J* = 7.4 Hz, 3H), 1.19 (d, *J* = 6.4 Hz, 3H), 1.52 – 1.69 (m, 4H), 2.29 (s, 6H), 2.48 (s, 1H), 2.70 (dddd, *J* = 6.8, 8.0, 11.1, 38.0 Hz, 2H), 3.07 – 3.21 (m, 1H), 3.62 – 3.77 (m, 2H), 6.85 – 7.05 (m, 3H).



[0283]


[0284] **Compound 38. 1-(2,6-dimethylphenoxy)-N-propylpropan-2-amine**, was made following the general method above (38% yield) as a pale yellow oil that solidified over time. $R_f = 0.24$ (10% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.03 – 6.90 (m, 3H, *H*Ar), 3.70 (m, 2H, CH₂), 3.17 (m, 1H, CH), 2.82-2.62 (m, 2H, CH₂), 2.50 (broad s, 1H), 2.31 (s, 6H, 2 x CH₃), 1.62 (m, 2H, CH₂), 1.28 (d, $J = 6.6$ Hz, 3H, CH₃), 0.99 (t, $J = 7.4$ Hz, 3H, CH₃) ppm.

[0285]




[0286] **Compound 39. 1-(2,6-dimethylphenoxy)-N-butylpropan-2-amine**, was made according to the general procedure above (60% yield) as a pale yellow oil that solidified over time. $R_f = 0.31$ (10% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.02 – 6.91 (m, 3H, *H*Ar), 4.21 (broad s, 1H, NH), 3.83-3.73 (AB of ABX, $J_{AB} = 9.6$ Hz, 2H, CH₂), 3.27 (m, 1H, CH), 2.95-2.76 (m, 2H, CH₂), 2.30 (s, 6H, 2 x CH₃), 1.65 (m, 2H, CH₂), 1.43 (m, 2H, CH₂), 1.28 (d, $J = 6.6$ Hz, 3H, CH₃), 0.98 (t, $J = 7.2$ Hz, 3H, CH₃) ppm.

[0287]




[0288] **Compound 40. 1-(2,6-dimethylphenoxy)-*N*-methoxy-ethyl-2-amine**, $R_f = 0.36$ (10% MeOH in DCM); ^1H NMR (300 MHz, CDCl_3) δ 7.02 – 6.89 (m, 3H, *H*Ar), 3.76-3.67 (m, 2H, CH_2), 3.59 (app t, $J = 4.9$ Hz, 2H), 3.40 (s, 3H, OCH_3), 3.22-3.12 (m, 2H, CH_2), 3.01-2.85 (m, 2H, CH_2), 2.54 (broad s, 1H, *NH*), 2.31 (s, 6H, 2 x CH_3), 1.22 (d, $J = 6.6$ Hz, 3H, CH_3) ppm.




[0289]

[0290] **Compound 41. 1-(2,6-dimethylphenoxy)-*N*-ethylpropan-2-amine**, was made following the general method above (40% yield) as a pale yellow oil that solidified over time. $R_f = 0.19$ (10% MeOH/ CH_2Cl_2): ^1H NMR (300 MHz, CDCl_3) δ 7.02 – 6.92 (m, 3H, *H*Ar), 6.23 (broad s, 1H), 4.03-3.96 (AB of ABX, $J_{\text{AB}} = 10.1$ Hz, 2H, CH_2), 3.61 (m, 1H, CH), 3.24 (m, 2H, CH_2), 2.30 (s, 6H, 2 x CH_3), 1.51 (d, $J = 6.9$ Hz, 3H, CH_3), 1.45 (t, $J = 6.4$ Hz, 3H, CH_3) ppm.




[0291]

[0292] **Compound 42. 1-(2,6-dimethylphenoxy)-*N*-benzylpropan-2-amine**, was made according to the above general procedure (80% yield) as a beige solid. $R_f = 0.24$ (5% MeOH/ CH_2Cl_2): ^1H NMR (300 MHz, CDCl_3) δ 7.40–7.3 (m, 4H, *H*Ar), 7.27 (m, 1H, *H*Ar, overlapping with solvent signal), 7.01 (m, 2H, *H*Ar), 6.93 (m, 1H, *H*Ar), 4.00-3.87 (AB quartet, $J = 13.1$ Hz, 2H, CH_2), 3.77-3.69 (m, 2H, CH_2), 3.20 (m, 1H, CH), 2.29 (s, 6H, 2 x CH_3), 1.22 (d, $J = 6.0$ Hz, 3H, CH_3) ppm.



[0293]


[0294] **Compound 43.** 1-(2,6-dimethylphenoxy)-*N*-phenylpropan-2-amine, was made according to the general method above (61% yield) as a pale yellow oil. *R_f* = 0.34 (20% EtOAc/hexanes): ¹H NMR (300 MHz, CDCl₃) δ 7.20 (t, *J* = 7.7 Hz, 2H, *H*Ar), 7.00 (m, 2H, *H*Ar), 6.92 (m, 1H, *H*Ar), 6.75-6.69 (m, 3H, *H*Ar), 4.13 (broad s, 1H), 3.89 (m, 1H, *CH*), 3.85-3.80 (m, 2H, *CH*₂), 2.27 (s, 6H, 2 x *CH*₃), 1.47 (d, *J* = 6.6 Hz, 3H, *CH*₃) ppm.



[0295]


[0296] **Compound 44.** 1-(2,6-dimethylphenoxy)-*N*-(2-phenylethyl)propan-2-amine, was made according to the above procedure (66% yield) as a beige solid. *R_f* = 0.25 (5% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.31 (m, 2H, *H*Ar), 7.26 (m, 2H, *H*Ar, overlapping with solvent signal), 7.22 (t, *J* = 7.1 Hz, 1H, *H*Ar), 7.01 (m, 2H, *H*Ar), 6.92 (m, 1H, *H*Ar), 3.67 (m, 2H, *CH*₂), 3.15 (m, 1H, *CH*), 3.06 (m, 1H, *CH*), 2.96-2.83 (m, 2H, *CH*₂), 2.25 (s, 6H, 2 x *CH*₃), 1.18 (d, *J* = 6.1 Hz, 3H, *CH*₃) ppm.

[0297] **Compound 45.** ¹H NMR (499 MHz, Chloroform-*d*) δ 1.15 – 1.33 (m, 5H), 1.72 (dd, *J* = 5.6, 9.7 Hz, 4H), 1.82 – 1.90 (m, 1H), 1.93 (d, *J* = 4.6 Hz, 1H), 3.22 (tt, *J* = 4.1, 9.5 Hz, 1H), 4.00 (s, 1.6H), 4.35 (s, 0.4H), 5.05 (s, 0.4H), 5.11 (s, 1.6H), 7.25 – 7.39 (m, 5H).



[0298]

[0299] **Compound 46.** $R_f = 0.56$ (5% ethyl acetate/hexanes); ^1H NMR (300 MHz, CDCl_3 , 2 isomers) δ 7.41-7.28 (m, 10H, *H*Ar), 7.03-6.90 (m, 6H, *H*Ar), 5.16 (s, 2H, CH_2), 5.03 (s, 2H, CH_2), 4.65 (s, 2H, CH_2), 4.15 (s, 2H, CH_2), 2.41 (m, 1H, *CH*), 2.31 (s, 6H, 2 x CH_3), 2.27 (s, 6H, 2 x CH_3), 2.05 (m, 1H, *CH*), 1.18 (m, 2H), 1.03-0.94 (m, 4H), 0.92-0.85 (m, 2H) ppm.




[0300]

[0301] **Compound 47.** 1-(pyridin-2-yloxy)propan-2-one *O*-benzyl oxime, $R_f = 0.28$ (75% ethyl acetate/hexanes); ^1H NMR (300 MHz, CDCl_3) δ 7.37-7.30 (m, 5H, *H*Ar), 7.19 (m, 1H, *H*Ar), 6.60 (m, 1H, *H*Ar), 6.16 (td, $J = 6.8, 1.3$ Hz, 1H, *H*Ar), 5.12 (s, 2H, CH_2), 4.70 (s, 2H, CH_2), 1.89 (s, 3H, CH_3) ppm.


[0302] **General Procedure for synthesis of (Pyridin-2-yloxy)propan-2-amine, Compound 48.** A 1M solution of borane-tetrahydrofuran complex in THF (5.0 eq.) was added to a stirred solution of 1-(pyridin-2-yloxy)propan-2-one *O*-benzyl oxime (1.0 eq.) in THF (3.8 mL) at 21 °C. After 14 hours, the reaction was stopped by dropwise addition of 1 M $\text{HCl}_{(\text{aq})}$ (pH 3) and then 10% (wt/wt) $\text{Na}_2\text{CO}_{3(\text{aq})}$ was added (pH 9), Celite (3 mL) was added, concentrated and dry-loaded onto a silica gel column and flashed using gradient elution (10% methanol in CH_2Cl_2 initial, then 1% $\text{NH}_4\text{OH}_{(\text{aq})}$ /20% MeOH/79% CH_2Cl_2). The isolated product was dissolved in 20% MeOH/ CH_2Cl_2 , filtered through a Whatman #1 filter paper and concentrated to give **23** (50% yield) as a pale yellow solid. For **23**: $R_f = 0.46$ (1% $\text{NH}_4\text{OH}_{(\text{aq})}$ /20% MeOH/79% CH_2Cl_2): ^1H NMR (300 MHz, CD_3OD) δ 7.69 (dd, $J = 6.6, 1.9$ Hz, 1H, *H*Ar), 7.57 (overlapping ddd, $J = 9.0, 6.8, 2.2$ Hz, 1H, *H*Ar), 6.58 (d, $J = 7.8$ Hz, 1H, *H*Ar), 6.44 (td, $J = 6.6, 1.1$ Hz, 1H, *H*Ar), 4.32-4.16 (AB of ABX, $J_{\text{AB}} = 14.0$ Hz, 2H, CH_2),

3.76 (m, 1H, CH), 1.36 (d, $J = 6.9$ Hz, 1H, CH₃) ppm. ESI/MS for C₈H₁₂N₂O : *calc.* [M+H]⁺ = 153.1, *found* m/z = 153.1.




[0303]

[0304] **Compound 49. 1-(2-Propylphenoxy)propan-2-amine** was made following the above procedure (94% yield) as a pale yellow oil. $R_f = 0.24$ (15% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.15 (m, 2H, HAr), 6.89 (td, $J = 7.4, 1.4$ Hz, 1H, HAr), 6.82 (m, 1H, HAr), 3.92-3.70 (AB of ABX, $J_{AB} = 8.8$ Hz, 2H, CH₂), 3.41 (m, 1H, CH), 2.64 (t, $J = 7.5$ Hz, 2H, CH₂), 1.64 (m, 2H, CH₃), 1.23 (d, $J = 6.6$ Hz, 1H, CH₃), 0.98 (t, $J = 7.1$ Hz, 3H, CH₃) ppm. ESI/MS for C₁₂H₁₉NO : *calculated* [M+H]⁺ = 194.1, *found* m/z = 194.1.



[0305]


[0306] **Compound 50. 1-(2-Ethylphenoxy)propan-2-amine** was made according to the procedure above (76% yield) as a pale yellow oil. $R_f = 0.22$ (15% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.16 (m, 2H, HAr), 6.92 (td, $J = 7.4, 1.1$ Hz, 1H, HAr), 6.82 (dd, $J = 8.8, 0.9$ Hz, 1H, HAr), 3.92-3.71 (AB of ABX, $J_{AB} = 9.0$ Hz, 2H, CH₂), 3.41 (m, 1H, CH), 2.69 (q, $J = 7.5$ Hz, 2H, CH₂), 1.24 (t, $J = 7.5$ Hz, 3H, CH₃), 1.23 (d, $J = 6.6$ Hz, 1H, CH₃) ppm. ESI/MS for C₁₁H₁₇NO : *calculated* [M+H]⁺ = 180.1, *found* m/z = 180.1.



[0307]

[0308] **Compound 51. 1-(2-(Trifluoromethyl)phenoxy)propan-2-amine** was made by the general procedure (71% yield) as a pale yellow oil. $R_f = 0.16$ (15% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 7.57 (dd, $J = 7.7, 1.3$ Hz, 1H, HAr), 7.48 (m, 1H, HAr), 7.00 (m, 2H, HAr), 4.03-3.76 (AB of ABX, $J_{AB} = 8.5$ Hz, 2H, CH₂), 3.44 (m, 1H, CH), 1.23 (d, $J = 6.6$ Hz, 1H, CH₃) ppm. ESI/MS for C₁₀H₁₂F₃NO : *calc.* [M+H]⁺ = 220.1, *found* m/z = 220.0.

[0309]



[0310] **Compound 52.** **1-(2-Methoxyphenoxy)propan-2-amine** was made


following the general procedure above (74% yield) as a pale yellow oil. $R_f = 0.29$ (15% MeOH/CH₂Cl₂): ¹H NMR (300 MHz, CDCl₃) δ 6.96-6.88 (m, 4H, *H*Ar), 3.98-3.70 (AB of ABX, $J_{AB} = 9.4$ Hz, 2H, CH₂), 3.88 (s, 3H, OCH₃), 3.41 (m, 1H, CH), 1.20 (d, $J = 6.6$ Hz, 1H, CH₃) ppm. ESI/MS for C₁₀H₁₅NO₂: *calculated* [M+H]⁺ = 182.1, *found* m/z = 182.0.

[0311] **Compound 53.** ¹H NMR (300 MHz, Chloroform-*d*) δ 1.41 (d, $J = 6.8$ Hz, 2H), 2.04 (s, 3H), 2.26 (s, 6H), 3.66 – 3.86 (m, 2H), 4.28 – 4.44 (m, 1H), 5.93 (s, 1H), 6.86 – 7.08 (m, 3H).

[0312] **Compound 54.** ¹H NMR (300 MHz, Chloroform-*d*) δ 1.54 (d, $J = 6.8$ Hz, 3H), 2.28 (s, 6H), 3.78 – 4.00 (m, 2H), 3.90 (s, 2H), 3.95 (dd, $J = 3.8, 9.1$ Hz, 1H), 4.57 (m, 1H), 6.64 (d, $J = 8.4$ Hz, 1H), 6.87 – 7.05 (m, 3H), 7.38 – 7.57 (m, 3H), 7.73 – 7.92 (m, 2H).

[0313] **Compound 55.** ESI/MS *calculated* for C₁₁H₁₇NO m/z : 179.1, *found* m/z = 180.0 [M+H]⁺

[0314] **Compound 56.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 1.45 (dd, $J = 1.5, 6.7$ Hz, 3H), 2.35 (s, 3H), 3.85 – 4.20 (m, 2H), 7.04 (t, $J = 7.7$ Hz, 1H), 7.17 (d, $J = 6.7$ Hz, 1H), 7.25 (d, $J = 7.4$ Hz, 1H).



[0315] **Compound 57.** **(S)-1-(2-chloro-6-methylphenoxy)propan-2-amine hydrochloride**, ESI/MS: *calculated* C₁₀H₁₄ClNO m/z = 199.1, *found* m/z = 200.0 [M+1] ¹H NMR (MeOH-*d*₆): 1.32 (d, $J = 6.2$ Hz, 3H), 2.32 (s, 3H), 3.82 – 3.96 (m, 3H), 4.18 (bs, 1H), 6.94 (t, $J = 7.8$ Hz, 1H), 7.04 – 7.08 (m, 1H), 7.17 – 7.21 (m, 1H).


[0316] **Compound 58.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 1.45 (d, $J = 6.7$ Hz, 2H), 3.70 – 3.81 (m, 1H), 4.06 (dd, $J = 6.7, 10.2$ Hz, 1H), 4.24 (dd, $J = 3.8, 10.2$ Hz, 1H), 7.01 (td, $J = 1.4, 7.6$ Hz, 1H), 7.13 (dd, $J = 1.5, 8.3$ Hz, 1H), 7.23 – 7.35 (m, 1H), 7.40 (dd, $J = 1.6, 7.9$ Hz, 1H).

[0317] **Compound 59.** ^1H NMR (300 MHz, Chloroform-*d*) δ 2.29 (t, J = 0.6 Hz, 6H), 4.30 (s, 2H), 6.92 – 7.08 (m, 3H).

[0318] **Compound 60.** ESI/MS calculated for $\text{C}_{13}\text{H}_{19}\text{NO}$ m/z : 205.2, found m/z = 206.0


[M+H]⁺ **Compound 61.** ESI/MS calculated for $\text{C}_{13}\text{H}_{19}\text{NO}$ m/z : 205.2, found m/z = 206.0
[M+H]⁺

[0319] **Compound 62.** ESI/MS calculated for $\text{C}_{13}\text{H}_{19}\text{NO}$ m/z : 205.2, found m/z = 206.0
[M+H]⁺



[0320]

[0321] **Compound (R-) 63a. (R)-1-cyclopropyl-2-(3,5-dimethylphenoxy)ethan-1-amine hydrochloride**, Prepared from (*R_cS_s*)-5 using the general procedure provided (*R*)-1 hydrochloride (47% yield). LRMS (ESI-TOF) m/z calc for $\text{C}_{13}\text{H}_{19}\text{NO}$ [M+H]⁺ 206.2; found 206.0.




[0322]

[0323] **Compound (S)-63b. (S)-1-cyclopropyl-2-(2,6-dimethylphenoxy)ethan-1-amine hydrochloride**, Prepared from (*S_cS_s*)- using the above method, (49% yield). $[\alpha]_D^{20}$ +30 (*c* 0.36, CH_3OH); ^1H NMR (300 MHz, CDCl_3): δ 8.67 (b, 2H), 6.68 (s, 2H), 6.58 (s, 1H), 4.26 (m, 1H), 4.13 (m, 1H), 2.26 (s, 6H), 1.15 (m, 1H), 0.53 (m, 3H), 0.16 (m, 1H) ppm. LRMS (ESI-TOF) m/z calc for $\text{C}_{13}\text{H}_{19}\text{NO}$ [M+H]⁺ 206.2; found 206.0.

[0324] **Compound 64.** ^1H NMR (300 MHz, Methanol-*d*₄) δ 1.44 (d, J = 6.7 Hz, 3H), 2.24 (broad s, 6H), 3.73 (pd, J = 3.7, 6.7 Hz, 1H), 3.96 (dd, J = 6.8, 10.3 Hz, 1H), 4.13 (dd, J = 3.8, 10.3 Hz, 1H), 6.79 (d, J = 7.9 Hz, 1H), 6.89 – 7.00 (m, 2H).

[0325] **Compound 65.** ^1H NMR (300 MHz, Methanol-*d*₄) δ 0.45 – 0.63 (m, 2H), 0.78 (ddd, J = 2.0, 3.8, 8.0 Hz, 2H), 1.11 (m, 1H), 2.24 (broad s, 6H), 2.84 (ddd, J = 3.4, 6.3, 10.0 Hz, 1H), 4.06 – 4.28 (m, 2H), 6.77 – 6.86 (m, 1H), 6.90 – 7.00 (m, 2H).

[0326] **Compound 66.** ^1H NMR (300 MHz, Methanol- d_4) δ 2.23 (d, J = 2.1 Hz, 6H), 4.22 – 4.36 (m, 2H), 4.79 (dd, J = 4.9, 7.1 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 6.94 (m, 2H), 7.42 – 7.60 (m, 5H).




[0327]

[0328] **Compound 67. 1-(2,6-dimethylphenoxy)-N-butylpropan-2-amine** was made according to the general method above (52% yield) as a pale yellow oil that solidified over time. R_f = 0.36 (10% MeOH/ CH_2Cl_2): ^1H NMR (300 MHz, CDCl_3) δ 7.02 – 6.89 (m, 3H, H_{Ar}), 3.76–3.67 (m, 2H, CH_2), 3.59 (app t, J = 4.9 Hz, 2H), 3.40 (s, 3H, OCH_3), 3.22–3.12 (m, 2H, CH_2), 3.01–2.85 (m, 2H, CH_2), 2.54 (broad s, 1H, NH), 2.31 (s, 6H, 2 x CH_3), 1.22 (d, J = 6.6 Hz, 3H, CH_3) ppm.


[0329] **Compound 68.** ^1H NMR (300 MHz, Methanol- d_4) δ 0.14 – 0.82 (m, 9H), 0.91 – 1.09 (m, 1H), 2.25 (s, 6H), 2.75 – 2.91 (m, 1H), 2.99 – 3.15 (m, 1H), 3.16 – 3.32 (m, 1H), 3.36 (dd, J = 1.2, 4.5 Hz, 1H), 3.54 (td, J = 2.2, 4.9 Hz, 1H), 3.80 – 4.14 (m, 2H), 6.54 (s, 2H), 6.56 (d, J = 4.9 Hz, 1H).

[0330] **Compound 69.** ^1H NMR (300 MHz, MeOH- d_4) δ 2.24 (d, J = 0.7 Hz, 6H), 2.53 – 2.76 (m, 1H), 3.35 (s, 1H), 3.33 – 3.56 (m, 2H), 3.96 – 4.13 (m, 2H), 6.49 – 6.61 (m, 3H), 7.22 – 7.47 (m, 5H).



[0331]

[0332] **Compound 70. (rac)-(+)-2-(3,5-dimethylphenoxy)-1-phenylethanamine hydrochloride.** Prepared from (*rac*)-**8** by the general procedure provided the title product (83% yield): ^1H NMR (300 MHz, CD_3OD): δ 7.56–7.46 (m, 5H), 6.64 (s, 3H), 4.74 (dd, J = 8.3, 4.4 Hz, 1H), 4.35–4.24 (AB of ABX, J_{AB} = 10.5 Hz, 2H), 2.27 (s, 6H) ppm. LRMS (ESI-TOF) m/z calc for $\text{C}_{16}\text{H}_{19}\text{NO}$ [$\text{M}+\text{H}^+$] 242.2; found 242.0.



[0333]

[0334] **Compound (R)-71. (R)-1-phenoxypropan-2-amine hydrochloride.** Prepared from (*R*_C, *S*_S)-**5** above using the general procedure provided (*R*)-**1** hydrochloride (65% yield): ¹H NMR (300 MHz, CD₃OD): δ 7.30 (m, 2H), 7.01-6.96 (m, 3H), 4.22-3.97 (AB of ABX, *J*_{AB} = 10.5 Hz, 2H), 3.73 (m, 1H), 1.44 (d, *J* = 6.9 Hz, 3H) ppm. LRMS (ESI-TOF) *m/z* calc. for C₉H₁₃NO [*M*+H⁺] 152.1; found 152.2.

[0335] **Compound 72.** ¹H NMR (300 MHz, MeOH-*d*₄) δ 1.44 (d, *J* = 6.7 Hz, 1H), 3.71 (ddd, *J* = 3.7, 7.1, 10.5 Hz, 0H), 4.00 (dd, *J* = 7.1, 10.3 Hz, 0H), 4.20 (dd, *J* = 3.6, 10.2 Hz, 1H), 7.00 (m, 3H), 7.30 (m, 2H).


[0336] **Compound 73.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 1.15 – 1.39 (m, 5H), 1.63 -2.05 (m, 6H), 2.30 (s, 6H), 3.41 (td, *J* = 3.7, 7.2 Hz, 1H), 3.66 (s, 1H), 3.86 – 4.05 (m, 1H), 6.87 – 7.07 (m, 2H).

[0337] **Compound 74.** ¹H NMR (300 MHz, CHCl₃-*d*) δ 0.14 – 0.45 (m, 2H), 0.45 – 0.92 (m, 3H), 2.27 (s, 3H), 2.34 (dt, *J* = 9.0, 2.7 Hz, 1H), 3.35 – 3.77 (m, 1H), 3.80 – 4.20 (m, 2H), 4.46 (dd, *J* = 2.6, 12.1 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.98 (dt, *J* = 7.6, 1.9 Hz, 1H), 7.06 (dt, *J* = 7.4, 1.2 Hz, 1H)

[0338] **Compound 75.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 2.19 (s, 3H), 2.24 (s, 3H), 4.18 – 4.37 (m, 2H), 4.73 (dd, *J* = 4.2, 8.4 Hz, 1H), 6.73 (dd, *J* = 2.8, 8.2 Hz, 1H), 6.82 (d, *J* = 2.7 Hz, 1H), 7.03 (d, *J* = 8.2 Hz, 1H), 7.42 – 7.58 (m, 5H).

[0339] **Compound 76.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 1.15 – 1.38 (m, 6H), 1.75 (d, *J* = 10.8 Hz, 1H), 1.88 (d, *J* = 9.7 Hz, 6H), 2.36 (s, 3H), 3.43 (td, *J* = 3.5, 7.0 Hz, 1H), 4.01 – 4.22 (m, 2H), 7.04 (t, *J* = 7.8 Hz, 1H), 7.12 – 7.31 (m, 2H).

[0340] **Compound 77.** ¹H NMR (300 MHz, Methanol-*d*₄) δ 0.54 (qd, *J* = 4.9, 10.2 Hz, 2H), 0.70 – 0.82 (m, 2H), 1.07 – 1.24 (m, 1H), 2.20 (s, 3H), 2.2.4 (s, 3H), 2.79 (ddd, *J* = 3.5, 7.0, 10.4 Hz, 1H), 4.09 (dd, *J* = 7.0, 10.3 Hz, 1H), 4.23 (dd, *J* = 3.5, 10.3 Hz, 1H), 6.72 (dd, *J* = 2.7, 8.2 Hz, 1H), 6.80 (d, *J* = 2.8 Hz, 1H), 7.03 (d, *J* = 8.2 Hz, 1H).




[0341]

[0342] **Compound 78.** 2-(3,5-bis(trifluoromethyl)phenoxy)-1-phenylethan-1-amine, ESI/MS: calc. $C_{16}H_{13}F_6NO$ $m/z = 349.1$, found $m/z = 350.0$ $[M+1]$ 1H NMR (300 MHz, $CHCl_3-d$) δ 4.02 (t, $J = 8.7$ Hz, 1H), 4.15 (dd, $J = 3.8, 8.7$ Hz, 1H), 4.48 (dd, $J = 3.8, 8.6$ Hz, 1H), 7.27 – 7.49 (m, 8H).


[0343] **Compound 79.** LRMS (ESI-TOF) m/z Expected $[M+H]^+ = 243$, Obs. $[M+H]^+ = 243$

[0344] **Compound 80.** 1H NMR (300 MHz, Chloroform- d) δ 2.62 – 2.85 (m, 3H), 3.38 (s, 3H), 3.50 (m, 3H), 4.08 – 4.21 (m, 3H), 7.27 (d, $J = 10.2$ Hz, 2H), 7.32 – 7.50 (m, 6H).




[0345]

[0346] **Compound 81.** 1-phenyl-2-(3-(trifluoromethyl)phenoxy)ethan-1-amine, ESI/MS: calculated $C_{15}H_{14}F_3NO$ $m/z = 281.1$, found $m/z = 282.0$ $[M+1]$




[0347]

[0348] **Compound 82.** 1-phenyl-2-(2-(trifluoromethyl)phenoxy)ethan-1-amine, ESI/MS: calculated $C_{15}H_{14}F_3NO$ $m/z = 281.1$, found $m/z = 282.0$ $[M+1]$



[0349] **Compound 83.** 2-methyl-N-(1-phenyl-2-(m-tolyloxy)ethyl)propane-2-amine, ESI/MS: calculated $C_{15}H_{17}NO$ $m/z = 227.1$, found $m/z = 228.0$ $[M+1]$.



[0350]

[0351] **Compound 84.** MS: $[M+H]^+ = 288$. Expected $[M+H]^+ = 288$

[0352] **Compound 85.** MS: $[M+H]^+ = 220$. Expected $[M+H]^+ = 220$

[0353] **Compound 86.** MS: $[M+H]^+ = 166$. Expected $[M+H]^+ = 166$

[0354] **Compound 87.** ^1H NMR (300 MHz, Chloroform- d) δ 0.63 – 1.41 (m, 5H), 1.09 (d, $J = 5.1$ Hz, 3H), 1.43– 2.0 (m, 5H), 3.07 – 3.31 (m, 2H), 3.37 – 3.50 (m, 1H)

[0355] **Compound 88.** A mixture of rotamers. ^1H NMR (300 MHz, Methanol- d_4) δ 2.14 – 2.40 (m, 3H), 4.17 – 4.26 (m, 2H), 4.32 – 4.49 (m, 1H), 7.50 – 7.72 (m, 6H), 7.83 – 8.29 (m, 2H).


[0356] **Compound 89.** ^1H NMR (300 MHz, Methanol- d_4) δ 1.07 – 1.54 (m, 5H), 1.64 - 1.98 (m, 6H), 2.28 (s, 6H), 3.32 (s, 3H), 4.04 – 4.23 (m, 2H), 6.58 – 6.67 (m, 3H).

[0357] **Compound 90.** ^1H NMR (300 MHz, Chloroform- d) δ 2.24 (s, 3H), 2.68 – 2.86 (m, 2H), 3.37 (s, 3H), 3.53 (td, $J = 1.4, 4.5, 5.0$ Hz, 2H), 4.02 – 4.19 (m, 2H), 4.21 (dd, $J = 4.1, 8.3$ Hz, 1H), 6.71 – 6.95 (m, 2H), 7.04 – 7.20 (m, 2H), 7.21 – 7.44 (m, 3H), 7.44 – 7.53 (m, 2H).

[0358] **Compound 91.** ^1H NMR (300 MHz, Chloroform- d) δ 6.68 (s, 2H), 6.58 (s, 1H), 4.04 - 4.37 (m, 3H), 2.26 (s, 6H), 0.52 (br. s., 4H), 0.16 (br. s., 1H)


[0359] **Compound 92.** ^1H NMR (300 MHz, CHCl_3 - d) δ 2.28 (s, 6H), 2.61 – 2.87 (m, 2H), 3.52 – 3.74 (m, 2H), 3.94 – 4.10 (m, 2H), 4.10 – 4.19 (m, 1H), 6.50 – 6.64 (m, 2H), 7.22 – 7.46 (m, 6H).

[0360] **Compound 93.** ESI/MS: MW calculated for $\text{C}_{18}\text{H}_{17}\text{F}_6\text{NO}_2$: 393.1 Observed: 394.0 $[M+H]^+$




[0361]

[0362] 2-(3-methylpyridin-2-yloxy)-1-phenylethanamine, KJO-VIII-068. ^1H NMR (CDCl_3): 2.19 (s, 3H), 2.74 (bs, 2H), 4.02 (dd, $J = 7.7$ Hz and 13.7 Hz, 1H), 4.41 (dd, $J = 2.7$ Hz and 13.7 Hz, 1H), 5.17 (dd, $J = 2.2$ Hz and 7.7 Hz, 1H), 6.05 (t, $J = 6.6$ Hz, 1H), 6.94 (d, $J = 6.6$ Hz, 1H), 7.23 (d, $J = 6.6$ Hz, 1H), 7.29 (t, $J = 7.1$ Hz, 1H), 7.35 (t, $J = 7.7$ Hz, 2H), 7.40 (d, $J = 7.1$ Hz, 2H).




[0363]

[0364] **Compound 94.** 2-((3-methylpyridin-2-yl)oxy)-1-phenylethan-1-amine, ESI/MS: calculated $C_{14}H_{14}N_2O_2$ $m/z = 228.1$, found $m/z = 229.0$ [M+1] 1H NMR (300 MHz, Chloroform-*d*) δ 2.10 (s, 3H), 4.19 (d, $J = 6.6$ Hz, 2H), 4.65 (t, $J = 6.5$ Hz, 1H), 5.95 (t, $J = 6.8$ Hz, 1H), 6.92 (d, $J = 6.8$ Hz, 1H), 7.16 (d, $J = 6.9$ Hz, 1H), 7.24 – 7.38 (m, 3H), 7.39 – 7.50 (m, 2H).




[0365]

[0366] **Compound 95.** 2-((4-methylpyridin-2-yl)oxy)-1-phenylethan-1-amine. ESI/MS: calculated $C_{14}H_{16}N_2O$ $m/z = 228.1$, found $m/z = 229.0$ [M+1]



[0367]

[0368] **Compound 96.** 1-phenyl-2-((3-(trifluoromethyl)pyridin-2-yl)oxy)ethan-1-amine, ESI/MS: calculated $C_{14}H_{13}F_3N_2O$ $m/z = 282.1$, found $m/z = 283.0$ [M+1]




[0369]

[0370] **Compound 97.** 1-phenyl-2-((4-(trifluoromethyl)pyridin-2-yl)oxy)ethan-1-amine. ESI/MS: calculated $C_{14}H_{13}F_3N_2O$ $m/z = 282.1$, found $m/z = 283.0$ [M+1]


[0371] **Compound 98.** 1H NMR (300 MHz, Methanol-*d*₄) δ 2.11 (s, 6H), 2.58 (m, 8H), 3.40 – 3.63 (m, 6H), 3.78 (s, 1H), 6.46 – 6.56 (m, 3H), 7.27 – 7.41 (m, 3H), 7.46 – 7.57 (m, 2H).

[0372] **Compound 99.** 1H NMR (300 MHz, Methanol-*d*₄) δ 3.49 (d, $J = 6.2$ Hz, 1H), 3.71 (s, 10H), 3.95 (m, 8H), 4.61 – 4.84 (m, 6H), 7.50 – 7.54 (m, 4H), 7.65 – 7.73 (m, 4H).



[0373] **Compound 100.** 1-(3-Methyl-pyridin-2-yloxy)propan-2-amine was made (31% yield) as a pale yellow solid: $R_f = 0.44$ (1% $\text{NH}_4\text{OH}_{(\text{aq})}$ /20% MeOH/ 79% CH_2Cl_2): ^1H NMR (300 MHz, CD_3OD) δ 7.45 (m, 1H, H_{Ar}), 7.39 (m, 1H, H_{Ar}), 6.30 (t, $J = 6.9$ Hz, 1H, H_{Ar}), 4.06-3.89 (AB of ABX, $J_{\text{AB}} = 12.8$ Hz, 2H, CH_2), 3.42 (m, 1H, CH), 1.17 (d, $J = 6.6$ Hz, 1H, CH_3) ppm. ESI/MS for $\text{C}_9\text{H}_{14}\text{N}_2\text{O}$: *calc.* $[\text{M}+\text{H}]^+ = 167.1$, *found* $m/z = 167.1$.


[0374] **Compound 105.** ^1H NMR (300 MHz, Chloroform- d) δ 2.62 – 2.83 (m, 2H), 3.37 (s, 3H), 3.44 – 3.56 (m, 2H), 4.07 (t, $J = 8.6$ Hz, 1H), 4.11 – 4.26 (m, 2H), 6.90 (d, $J = 8.3$ Hz, 1H), 6.94 – 7.05 (m, 1H), 7.25 – 7.46 (m, 3H), 7.45 (tt, $J = 1.4, 7.4$ Hz, 3H), 7.51 – 7.61 (m, 1H).



[0375]


Compound 110. ^1H NMR (499 MHz, CD_3OD) δ 8.32 - 8.41 (m, 1H), 8.25 - 8.32 (m, 1H), 7.44 - 7.69 (m, 4H), 7.38 (t, $J = 7.68$ Hz, 2H), 7.28 - 7.35 (m, 1H), 5.12 (dd, $J = 3.84, 7.68$ Hz, 1H), 4.72 - 4.79 (m, 2H), 4.29 - 4.47 (m, 2H), 3.57 - 3.78 (m, 2H), 3.39 (s, 3H). Calculated m/z for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: 272.15, Observed: 273.2 $[\text{M}+\text{H}]^+$, 295.3 $[\text{M}+\text{Na}]^+$

[0376]




[0377]

[0378] **Compound 111.** $R_f = 0.44$ (1:20 MeOH/DCM), purity 98%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.18 (d, $J = 4.8$ Hz, 1H), 7.55-7.18 (m, 7H), 4.57-4.40 (m, 2H), 2.43 (s, 3H). Calculated m/z for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}$ m/z : 228.1, found $m/z = 229.0$ $[\text{M}+\text{H}]^+$




Compound 112. $R_f = 0.45$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.47-8.26 (m, 2H), 7.85-7.30 (m, 6H), 5.11 (s, 1H), 4.35 (d, $J = 5.2$ Hz, 2H), 2.45 (s, 3H). Calculated m/z for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}$ m/z : 228.1, found $m/z = 229.0$ 0 $[\text{M}+\text{H}]^+$

[0379]




[0380]

[0381] **Compound 113.** $R_f = 0.43$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.98 (s, 3H), 8.10 (d, $J = 10.1$ Hz, 2H), 7.82 – 7.57 (m, 2H), 7.50-7.39 (m, 4H), 4.77 (s, 1H), 4.52-4.39 (m, 2H), 2.35 (s, 3H). Calculated m/z for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}$ m/z : 228.1, found $m/z = 229.0$ 0 $[\text{M}+\text{H}]^+$




[0382]

[0383] **Compound 114.** $R_f = 0.43$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.90 (s, 3H), 8.50 (s, 1H), 7.87 (d, $J = 8.9$ Hz, 1H), 7.66 (m, 3H), 7.45 (m, $J = 6.9$ Hz, 3H), 4.81 (s, 1H), 4.52 (m, $J = 5.3$ Hz, 2H), 2.48 (s, 3H). Calculated m/z for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}$ m/z : 228.1, found $m/z = 229.0$ 0 $[\text{M}+\text{H}]^+$




[0384]

[0385] **Compound 115.** $R_f = 0.45$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.37 (s, 1H), 7.91 – 7.21 (m, 7H), 4.52 – 4.37 (m, 2H). Calculated m/z for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$ m/z : 282.1, found $m/z = 283.0$ 0 $[\text{M}+\text{H}]^+$




[0386]

[0387] **Compound 116.** $R_f = 0.46$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.12 – 7.02 (m, 8H), 4.70-4.59 (m, 1H), 4.45-4.31 (m, 2H). Calculated m/z for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$ m/z : 282.1, found $m/z = 283.0$ $[\text{M}+\text{H}]^+$




[0388]

[0389] **Compound 117.** $R_f = 0.46$ (1:20 MeOH/DCM), purity 95%+. Entry #10, (Notebook: MEJ-I-077) ^1H NMR (300 MHz, DMSO- d_6) δ 8.92 (s, 3H), 8.31 (s, 1H), 7.92 (d, $J = 8.6$ Hz, 1H), 7.70-7.54 (m, 3H), 7.45 (m, 3H), 4.80 (s, 1H), 4.51 (m, $J = 5.1$ Hz, 2H), 2.46 (s, 3H). Calculated m/z for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$ m/z : 282.1, found $m/z = 283.0$ $[\text{M}+\text{H}]^+$




[0390]

[0391] **Compound 118.** $R_f = 0.45$ (1:20 MeOH/DCM), purity 98%+. ^1H NMR (300 MHz, Methanol- d_4) δ 7.98 (d, $J = 5.0$ Hz, 1H), 7.50 – 7.42 (m, 2H), 7.35 (dt, $J = 15.0, 7.0$ Hz, 3H), 7.07 (d, $J = 5.0$ Hz, 1H), 4.38 (t, $J = 5.8$ Hz, 1H), 3.94 (dd, $J = 5.8, 2.9$ Hz, 2H), 2.35 (s, 3H), 2.21 (s, 3H). Calculated m/z for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}$ m/z : 242.1, found $m/z = 243.0$ $[\text{M}+\text{H}]^+$




[0392]

[0393] **Compound 119.** $R_f = 0.45$ (1:20 MeOH/DCM), purity 98%+. ^1H NMR (300 MHz, Methanol- d_4) δ 7.55 – 7.11 (m, 7H), 4.68 (s, 1H), 4.52 – 4.37 (m, 2H), 2.62 (s, 3H), 2.41 (s, 3H). Calculated m/z for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}$ m/z : 242.1, found $m/z = 243.0$ $[\text{M}+\text{H}]^+$




[0394]

[0395] **Compound 120.** $R_f = 0.46$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, DMSO- d_6) δ 9.12 (s, 3H), 8.48 (s, 1H), 7.95 – 7.55 (m, 3H), 7.44 (m, 3H), 4.81 (s, 1H), 4.62 – 4.37 (m, 2H), 2.64 (s, 3H), 2.45 (s, 3H). Calculated m/z for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}$ m/z : 242.1, found $m/z = 243.0$ $[\text{M}+\text{H}]^+$




[0396]

Compound 121. ^1H NMR (499 MHz, CD_3OD) δ 8.32 - 8.41 (m, 1H), 8.25 - 8.32 (m, 1H), 7.44 - 7.69 (m, 4H), 7.38 (t, $J = 7.68$ Hz, 2H), 7.28 - 7.35 (m, 1H), 5.12 (dd, $J = 3.84, 7.68$ Hz, 1H), 4.72 - 4.79 (m, 2H), 4.29 - 4.47 (m, 2H), 3.57 - 3.78 (m, 2H), 3.39 (s, 3H); Calculated for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: 272.15 Observed: 273.2 $[\text{M}+\text{H}]^+$, 295.3 $[\text{M}+\text{Na}]^+$




[0397]

[0398] **Compound 122.** $R_f = 0.49$ (1:20 MeOH/DCM), purity 98%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.50-7.09 (bm, 7H), 5.10 (s, 1H), 4.18 (s, 2H), 3.81-3.68 (m, 2H), 3.51 (s, 2H), 3.29 (s, 3H), 2.61 (s, 3H), 2.43 (s, 3H). Calculated m/z for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2$ m/z : 300.18, found $m/z = 301.0$ $[\text{M}+\text{H}]^+$




[0399]

[0400] **Compound 123.** $R_f = 0.48$ (1:20 MeOH/DCM), purity 98%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.44 (s, 1H), 8.29 (s, 1H), 7.80 (s, 1H), 7.39 (m, 5H), 5.12 (s, 1H), 4.33 (d, $J = 5.2$ Hz, 2H), 3.61 (m, 4H), 3.38 (s, 3H), 2.48 (s, 3H). Calculated m/z for $\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}_2$ m/z : 286.17, found $m/z = 287.0$ $[\text{M}+\text{H}]^+$




[0401]


[0402] **Compound 124.** $R_f = 0.46$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.37 (s, 1H), 7.91 – 7.21 (m, 7H), 4.52 – 4.37 (m, 2H), 4.15-4.01 (m, 2H), 3.56-3.41 (m, 2H), 3.28 (s, 3H). Calculated m/z for $\text{C}_{17}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2$ m/z : 340.14, found $m/z = 341.0$ $[\text{M}+\text{H}]^+$



[0404] **Compound 125.** $R_f = 0.48$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, Methanol- d_4) δ 7.61 – 7.05 (m, 7H), 4.71-4.60 (m, 1H), 4.54 – 4.39 (m, 2H), 3.91-3.52 (m, 4H), 3.27 (s, 3H), 2.62 (s, 3H), 2.41 (s, 3H). Calculated m/z for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2$ m/z : 300.18, found $m/z = 301.0$ $[\text{M}+\text{H}]^+$




[0406] **Compound 126.** ^1H NMR (300 MHz, CD_3OD) δ 4.25 (d, $J = 10.3$ Hz, 1H), 4.32 (d, $J = 10.3$ Hz, 1H), 6.60 - 6.70 (m, 4H), 7.41 – 7.61 (m, 5H). ESI/MS calculated for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}$ m/z : 214.1, found $m/z = 215.0$ $[\text{M}+\text{H}]^+$




[0408] **Compound 127.** ^1H NMR (300 MHz, CD_3OD) δ 7.41 – 7.61 (m, 5H), 6.60 - 6.70 (m, 4H), 4.70 (br. s., 1H), 4.48 (br. s., 1H), 4.32 (br. s., 1H), 3.72 – 3.45 (m., 2H), 3.30 - 3.42 (m, 2H), 3.28 (s, 3H).

[0409] ESI/MS calculated for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$ m/z : 272.2, found $m/z = 273.1$ $[\text{M}+\text{H}]^+$




[0411] **Compound 128.** $R_f = 0.47$ (1:20 MeOH/DCM), purity 95%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.52 (d, $J = 5.1$ Hz, 1H), 7.63 – 7.22 (m, 6H), 6.75 (s, 1H), 4.71-4.63 (m, 1H), 4.49-4.34 (m, 2H). Calculated m/z for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$ m/z : 282.1, found $m/z = 283.0$ $[\text{M}+\text{H}]^+$




[0412]

[0413] **Compound 129.** $R_f = 0.50$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.80 (s, 3H), 8.44 (d, $J = 9.6$ Hz, 1H), 7.96 – 7.76 (m, 1H), 7.49 (m, 9H), 6.99 (d, $J = 7.5$ Hz, 1H), 4.90 (m, 1H), 4.46 (d, $J = 5.7$ Hz, 2H). Calculated m/z for $\text{C}_{18}\text{H}_{17}\text{NO}$ m/z : 263.1, found $m/z = 264.1$ $[\text{M}+\text{H}]^+$



[0414]


[0415] **Compound 130.** $R_f = 0.45$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, Methanol- d_4) δ 8.81 – 8.35 (m, 3H), 7.82 (dd, $J = 16.8, 10.6$ Hz, 3H), 7.63 (d, $J = 6.5$ Hz, 4H), 7.56 – 7.09 (m, 5H), 4.81 (s, 1H), 4.40 (s, 2H). Calculated m/z for $\text{C}_{18}\text{H}_{17}\text{NO}$ m/z : 263.1, found $m/z = 264.1$ $[\text{M}+\text{H}]^+$



[0416]


[0417] **Compound 131.** $R_f = 0.52$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.95 (s, 3H), 8.15 (s, 1H), 7.97 (m, 3H), 7.77 (d, $J = 8.5$ Hz, 1H), 7.57 (dd, $J = 5.7, 3.8$ Hz, 2H), 7.01 – 6.87 (m, 3H), 4.90 (s, 1H), 4.38 – 4.00 (m, 2H), 2.10 (s, 6H). Calculated m/z for $\text{C}_{20}\text{H}_{21}\text{NO}$ m/z : 291.16, found $m/z = 292.10$ $[\text{M}+\text{H}]^+$

[0418]




[0419]

[0420] **Compound 132.** $R_f = 0.60$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.87 – 8.42 (m, 3H), 8.12 (s, 1H), 8.09 – 7.85 (m, 4H), 7.71 (s, 4H), 7.58 (d, $J = 9.4$ Hz, 1H), 4.94 (s, 1H), 4.61 (s, 2H). Calculated m/z for $\text{C}_{20}\text{H}_{15}\text{F}_6\text{NO}$ m/z : 399.1, found $m/z = 400.1$ $[\text{M}+\text{H}]^+$




[0421]

[0422] **Compound 133.** $R_f = 0.48$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.83 (s, 3H), 8.14 (s, 1H), 8.06 – 7.85 (m, 3H), 7.75 (d, $J = 8.6$ Hz, 1H), 7.57 (dd, $J = 6.2, 3.3$ Hz, 2H), 7.11 (d, $J = 7.4$ Hz, 2H), 6.95 (d, $J = 7.5$ Hz, 1H), 6.85 (t, $J = 7.0$ Hz, 1H), 4.92 (s, 1H), 4.39 (d, $J = 5.5$ Hz, 2H), 2.17 (s, 3H). Calculated m/z for $\text{C}_{19}\text{H}_{19}\text{NO}$ m/z : 277.15, found $m/z = 278.1$ $[\text{M}+\text{H}]^+$



[0423]


[0424] **Compound 134.** $R_f = 0.5$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.77 (s, 3H), 8.10 (s, 1H), 8.04 – 7.85 (m, 3H), 7.71 (d, $J = 8.7$ Hz, 1H), 7.68 – 7.48 (m, 3H), 7.39 – 7.28 (m, 2H), 7.13 (t, $J = 7.4$ Hz, 1H), 4.87 (s, 1H), 4.58 (dd, $J = 9.9, 5.9$ Hz, 2H). Calculated m/z for $\text{C}_{19}\text{H}_{16}\text{F}_3\text{NO}$ m/z : 331.12, found $m/z = 332.1$ $[\text{M}+\text{H}]^+$




[0425]

[0426] **Compound 135.** $R_f = 0.50$ (1:20 MeOH/DCM), purity 97%+. ^1H NMR (300 MHz, DMSO- d_6) δ 8.89 (s, 3H), 8.13 (s, 1H), 8.08 – 7.85 (m, 3H), 7.75 (dd, $J = 8.5, 1.7$ Hz, 1H),

7.57 (dd, $J = 5.6, 3.8$ Hz, 2H), 6.61 (d, $J = 5.0$ Hz, 3H), 4.85 (t, $J = 6.0$ Hz, 1H), 4.51 – 4.18 (m, 2H), 2.22 (s, 6H). Calculated m/z for $C_{20}H_{21}NO$ m/z : 291.16, found $m/z = 292.10$ $[M+H]^+$



[0428] **Compound 136.** $R_f = 0.57$ (9:1 $CH_2Cl_2:CH_3OH$) 1H NMR (499 MHz, methanol- d_4) δ 7.57 (d, 2 H), 7.54 - 7.43 (m, 3 H), 7.07 - 6.97 (m, 2 H), 6.97 - 6.89 (m, 1 H), 4.19 - 4.11 (d, 1 H, $J = 10$ Hz), 4.08 (d, 1 H, $J = 10$ Hz), 2.20 (s, 6 H); m/z calculated for $C_{16}H_{18}DNO$: 242.15. Observed for $[M+H]^+$: 243.4.




[0430] **Compound 137.** $R_f = 0.52$ (9:1 $CH_2Cl_2:CH_3OH$); 1H NMR (499 MHz, methanol- d_4) δ 6.98 - 7.11 (m, 2H), 6.89 - 6.99 (m, 1H), 3.86 - 3.96 (m, 1H), 3.77 - 3.86 (m, 1H), 2.30 (s, 6H), 1.44 (s, 3H); m/z calculated for $C_{11}H_{16}DNO$: 180.14. Observed for $[M+H]^+$: 181.2.

EXAMPLE 4. PREPARATION OF ENANTIOMERS OF MEXILETINE

[0431] Enantiomers of Mexiletine analogs (Scheme 1 and 2) were prepared by $NaBH_4$ reduction of the starting ketone **A** to give the racemic alcohol **B**. **B** and N,N' -diisopropylcarbodiimide were combined (catalyzed by $CuCl$), heated with (*R*)-mandelic acid in toluene at $150^\circ C$ to afford **S-C** and **R-C**, that were separated via chromatography. Each diastereomer was hydrolyzed with $NaOH_{aq}$ ($MeOH:THF$), subjected to Mitsunobu reaction conditions in the presence of phthalimide, and treated with excess hydrazine. Each amine in ether was treated with 4M HCl in dioxane at RT to give HCl salts of the enantiomers (**R-D** and **S-D**).

[0432] **SCHEME 1**



* (a) NaBH_4 , MeOH, RT (b) (i) Diisopropylcarbodiimide, CuCl, 100 °C, 5 min uwave. (ii) (*R*)-Mandelic acid, toluene, 150 °C, 5 min uwave. (c) (*R*)-Mandelic acid, HBTU, DMF, RT. (d) NaOH, $\text{H}_2\text{O}:\text{CH}_3\text{OH}:\text{THF}$, RT. (e) (i) Phthalimide, triphenylphosphine, diisopropylazodicarboxylate, THF, RT; (ii) Hydrazine hydrate, EtOH, 75 °C; (iii) HCl in dioxane, ether, RT.

[0433] **Table 1. Substituents for Mexiletine enantiomers in Schemes 1 and 2.**


	R₁	R₂	R₃
Da	H	CF ₃	CF ₃
Db	H	CH ₃	CH ₃
Dc	CH ₃	H	H
Dd	CF ₃	H	H

[0434]

[0435] Ketone A was treated with chiral *t*-butylsulfonamide catalyzed by $\text{Ti}(\text{OEt})_4$ followed by NaBH_4 reduction led to a mixture of diastereomeric sulfonamides separated via

chromatography. Treatment of each sulfonamide with HCl in dioxane followed by treatment with Et₂O gave the individual enantiomers (*S*)-**D** and (*R*)-**D**.

[0436] **SCHEME 2***



* (a) (i) (*R*)-2-methylpropane-2-sulfonamide, Ti(OEt)₄, 90 °C (uwave), 1h, (ii) NaBH₄, CuSO₄, THF, RT (b) HCl in dioxane, Et₂O, RT.

[0437] **Chiral amine (S)-Da.** ¹H NMR (300 MHz, Chloroform-d) δ 4.52 – 4.63 (m, 1H), 5.29 (t, *J* = 9.6 Hz, 1H), 5.80 (dd, *J* = 5.3, 10.1 Hz, 1H), 7.24 – 7.26 (m, 4H), 7.26 – 7.31 (s, 2H), 7.31 – 7.49 (m, 3H), 7.58 (d, *J* = 6.6 Hz, 1H), 7.68 – 7.79 (m, 1H), 7.78 – 7.89 (m, 1H). ESI MS: Calculated *m/z* for C₁₆H₁₃F₆NO: 349.1 Observed: 350.2 [M+H]⁺. ¹H NMR of the HCl salt (300 MHz, MeOH-d₄) δ 4.44 – 4.62 (m, 2H), 4.78 – 4.84 (m, 1H), 7.30 – 7.95 (m, 8H). [α]₅₄₆₂₀ = -17° (c = 0.08; CD₃OD).

[0438] **Chiral amine (R)-Da.** ¹H NMR (300 MHz, MeOH-d₄) δ 4.44 – 4.62 (m, 2H), 4.78 – 4.84 (m, 1H), 7.30 – 7.95 (m, 8H). ESI MS: Calculated *m/z* for C₁₆H₁₃F₆NO: 349.1 Observed: 350.2 [M+H]⁺. [α]₅₄₆₂₀ = +19° (c = 0.08; CD₃OD).

[0439] **Chiral amine (R)-Db.** ¹H NMR (300 MHz, MeOH-d₄) δ 2.27 (d, *J* = 0.7 Hz, 6H), 4.18 – 4.38 (m, 2H), 4.73 (dd, *J* = 4.1, 8.4 Hz, 1H), 6.64 (s, 3H), 7.42 – 7.58 (m, 4H). Calculated *m/z* for C₁₆H₁₉NO: 241.1 Observed: 242.1 [M+H]⁺. [α]₅₄₆₂₀ = -30° (c = 0.1; CD₃OD).

[0440] **Chiral amine (S)-Db.** ¹H NMR (300 MHz, MeOH-d₄) δ 2.27 (d, *J* = 0.7 Hz, 6H), 4.18 – 4.38 (m, 2H), 4.73 (dd, *J* = 4.1, 8.4 Hz, 1H), 6.64 (s, 3H), 7.42 – 7.58 (m, 4H). Calculated *m/z* for C₁₆H₁₉NO: 241.1 Observed: 242.1 [M+H]⁺. [α]₅₄₆₂₀ = +32.3° (c = 0.1; CD₃OD).

[0441] **Chiral amine (R)-Dc.** ^1H NMR (300 MHz, MeOH- d_4) δ 2.27 (s, 3H), 3.44 (s, 2H), 4.26 – 4.40 (m, 1H), 6.83 – 6.97 (m, 1H), 7.08 – 7.19 (m, 1H), 7.42 – 7.60 (m, 2H). Calculated m/z for $\text{C}_{15}\text{H}_{17}\text{NO}$: 227.1 Observed: 228.1 $[\text{M}+\text{H}]^+$. $[\alpha]_{589}^{20} = -12^\circ$ ($c = 0.1$; CD_3OD).

[0442] **Chiral amine (S)-Dc.** ^1H NMR (300 MHz, MeOH- d_4) δ 2.27 (s, 3H), 3.44 (s, 2H), 4.26 – 4.40 (m, 1H), 6.83 – 6.97 (m, 1H), 7.08 – 7.19 (m, 1H), 7.42 – 7.60 (m, 2H). Calculated m/z for $\text{C}_{15}\text{H}_{17}\text{NO}$: 227.1 Observed: 228.1 $[\text{M}+\text{H}]^+$. $[\alpha]_{589}^{20} = +15^\circ$ ($c = 0.1$; CD_3OD).

[0443] **Chiral amine (S)-Dd.** ^1H NMR (300 MHz, MeOH- d_4) δ 4.43 – 4.53 (m, 2H), 4.77 – 4.85 (m, 1H), 7.09 – 7.31 (m, 2H) 7.43 – 7.53 (m, 1H), 7.48 – 7.67 (m, 1H). Calculated m/z for $\text{C}_{16}\text{H}_{19}\text{NO}$: 281.1 Observed: 282.1 $[\text{M}+\text{H}]^+$. $[\alpha]_{589}^{20} = +36^\circ$ ($c = 0.15$; CD_3OD).

Chiral amine (R)-Dd. ^1H NMR (300 MHz, MeOH- d_4) δ 4.43 – 4.53 (m, 2H), 4.77 – 4.85 (m, 1H), 7.09 – 7.31 (m, 2H) 7.43 – 7.53 (m, 1H), 7.48 – 7.67 (m, 1H). Calculated m/z for $\text{C}_{16}\text{H}_{19}\text{NO}$: 281.1 Observed: 282.2 $[\text{M}+\text{H}]^+$. $[\alpha]_{589}^{20} = -31^\circ$ ($c = 0.15$; CD_3OD). The enantiomers (i.e., (R)- and (S)-Da-Dd) were examined side by side for pharmacological response in cardiomyocytes derived from iPSCs from an LQT3 patient. For Da-Dd, it was observed that compared to the (R)-enantiomer, the (S)-enantiomer generally possessed much greater action potential shortening. This stereoselective result showed fundamental pharmacological interaction with the cellular target in the cells from the patient cohort. The interaction with the cells possesses significant stereoselectivity. However, this observation is surprising and unexpected because the clinically used material (i.e., (R)-Mexilitene) possesses the opposite apparent (and modest) stereoselectivity as observed for the more pharmacologically potent analogs described in this Example (i.e., Da to Dd). Further, (R)- and (S)-Mexilitene itself does not show significant stereoselectivity for shortening of the action potential in iPSCs-derived cardiomyocytes from an LQT3 patient (i.e., (R)-Mexilitene ratio is 1.3 and (S)-Mexilitene is 1.25 and racemic Mexilitene ratio is 1.3, see **Table 3, Example 1**, data for entries **1, 2a** and **2b**). This result may be due to the differences in the pharmacological preparations used in the experiments.

EXAMPLE 5: SEPARATION OF ENANTIOMERS OF MEXILETINE.

[0444] **Reverse phase HPLC analysis.** RPHPLC analysis of *N-tert*-butanesulfinyl amine derivatives of Mexilitene and analogs (**Example 4, Scheme 2**) was done on a Hitachi HPLC


using a Phenomenex Luna C18 column (5 μ m, 150 x 4.6 mm) using gradient elution at a flow rate of 1.0 mL/min. Compounds were eluted using a mobile phase gradient of 60/40 water/acetonitrile with 0.05% TFA to 20/80 water/acetonitrile with 0.05% TFA. UV detection was at 254 nm.


[0445] **Chiral phase HPLC analysis.** Mexiletine enantiomers and enantiomers of analogs were analyzed by HPLC on a Hitachi HPLC using a Phenomenex Lux Cellulose-1 column (5 μ m, 150 x 4.6 mm) with isocratic elution using a mobile phase of 75/20/5 hexanes/isopropanol/acetonitrile with 0.01% perchloric acid (70% aqueous solution) at a flow rate of 0.75 mL/min. UV detection was at 220 nm. On the basis of chiral phase HPLC, purity of Mexiletine enantiomers was observed to be >95%. Purity of synthetic Mexiletine analog enantiomers (RPHPLC) was observed to be >95%.

EXAMPLE 6: SYNTHESIS OF DEUTERATED COMPOUNDS FOR IMPROVED METABOLIC STABILITY

[0446] Deuterated compounds **104a-d** were synthesized according to **Scheme 1** (below). Ketones **101a-101d** were treated with NaBD₄ (>99% deuterium) in EtOH at RT to afford deuterio alcohols **102a-102d** that were treated with phthalimide, triphenylphosphine and diisopropyl azodicarboxylate in THF (72 h) to provide **103a-103d**. Treatment of **103a-103d** with hydrazine hydrate in refluxing EtOH (20 h) yielded the free base form of the amines that were converted to their corresponding HCl salts **104a-104d** by treatment with HCl in dioxane/ether (1 h, RT).

[0447] **Scheme 1**



[0448] **Table 1. Deuterated Analogs of Mexiletine Analogs**

Compd	R ₁	R ₂	R ₃
104 a	H	CF ₃	CF ₃
104 b	H	CH ₃	CH ₃
104 c	CH ₃	H	H
104 d	CF ₃	H	H

[0449] **Compound 104a.** (R₁ = H; R₂ = CF₃; R₃ = CF₃): ¹H NMR (300 MHz, MeOH-*d*₄) δ 4.48 (d, *J* = 10.4 Hz, 1H), 4.55 (d, *J* = 10.4 Hz, 1H), 7.42 – 7.59 (m, 4H), 7.61 – 7.65 (m, 4H). ESI/MS calcd. for C₁₆H₁₂DF₆NO *m/z* = 350.1, found *m/z* = 351.0 [M+H]⁺.

[0450] **Compound 104b** (R₁ = H; R₂ = CH₃; R₃ = CH₃): ¹H NMR (300 MHz, MeOH-*d*₄) δ 2.27 (s, 6H), 4.25 (d, *J* = 10.3 Hz, 1H), 4.32 (d, *J* = 10.3 Hz, 1H), 6.64 (s, 3H), 7.41 – 7.61 (m, 5H). ESI/MS calcd. for C₁₆H₁₈DNO *m/z*: 242.1, found *m/z* = 243.0 0 [M+H]⁺.

[0451] **Compound 104c** (R₁ = CH₃; R₂ = H; R₃ = H): ¹H NMR (300 MHz, MeOH-*d*₄) δ 2.27 (s, 3H), 4.34 (m, 2H), 6.77 – 7.01 (m, 2H), 7.02 – 7.30 (m, 2H), 7.30 – 7.76 (m, 2H). ESI/MS calcd. for C₁₆H₁₈DNO *m/z*: 228.1, found *m/z* = 229.0 [M+H]⁺

[0452] **Compound 104d** (R₁ = CF₃; R₂ = H; R₃ = H): ¹H NMR (300 MHz, MeOH-*d*₄) δ 4.47 (broad m, 2H), 7.09 – 7.20 (m, 1H), 7.24 (d, *J* = 8.2 Hz, 1H), 7.34 – 7.69 (m, 7H). ESI/MS calculated for C₁₅H₁₃DF₃NO *m/z*: 282.1, found *m/z* = 283.0 [M+H]⁺.

[0453] Because a prominent route of metabolism of Mexilitene and analogs involves C-H oxidation (alpha to the amine), replacement of the labile C-H bond with C-D decreases metabolism, decreases clearance and increases bioavailability and efficacy (also, see **Example 15**, below).

[0454] In biological testing in cardiomyocytes derived from iPSCs from an LQT3 patient, it was observed that compared to unlabeled compound, deuterium-labeled Mexilitene analogs (e.g., **104a** and **104b**) showed equal to or greater action potential shortening (**Table 1**). This result illustrates that deuterium labeling at the alpha position does not change the fundamental pharmacological interaction with the cellular target. However, a kinetic isotope effect on metabolism and decreased clearance of the molecule will be manifested in vivo to improve bioavailability and further improve efficacy.

[0455] **Table 1. Effect of Deuterated and Non-Deuterated Mexilitene Analogs on Cardiomyocytes.**

CPD ^{a,b}	Structure	WT-EC ₅₀ (μ M) -Prolong.	WT-Cess. Dose (μ M)	WT- Prolong. Dose (μ M)	LQT-EC ₅₀ (μ M)- Shortening	LQT- Cess. Dose (μ M)	LQT- Fold Shortening	LQT- Shortening Dose (μ M)
78	bis-CF ₃ racemic parent	No AP prolongation	133	No AP Prolong.	23.08	66	1.208	22
104a	bis-CF ₃ Deuterated	No AP prolongation	66	No AP Prolong.	No AP shortening	133	1.274	22
82	mono-CF ₃ racemic parent	No AP prolongation	66	No AP Prolong.	4.07	66	1.539	22
104d	mono-CF ₃ Deuterated	No AP prolongation	22	No AP Prolong.	(no EC ₅₀ -but shortens)	66	1.395	22
25	mono-CH ₃ racemic parent	1247	No EADs	4.07	996.9	1.539	1.606	22
104c	mono-CH ₃ Deuterated	No AP prolongation	66	No AP Prolong.	No AP shortening	22	No AP shortening	No AP shortening
70	bis-CH ₃ racemic parent	No AP prolongation	66	No AP Prolong.	< 0.8	66	1.279	7.4
104b	bis-CH ₃ Deuterated	No AP prolongation	22	No AP Prolong.	0.87	22	1.280	2.5

[0456] ^aNo EADs or Spiky Peaks for any compound; ^bNo AP Prolongation for any compound

[0457] **EXAMPLE 7: SYNTHESIS OF COMPOUNDS OF FORMULA III.**




The pyridinoxy propan-2-amine-based compounds (i.e., 2, 3 or 4-pyridin-ol Mexiletine analogs) of general formula III were synthesized according to the Schemes in **Example 3**.


EXAMPLE 8. METABOLIC AND CHEMICAL STABILITY

[0458] **Metabolic Stability Studies in the presence of Rat, Mouse or Human Liver Microsomes or S9.** A typical incubation contained rat, mouse, dog or human liver microsomes

(0.4-0.5 mg of protein), 100 mM potassium phosphate buffer (pH7.4), 50 μ M test compound, an NADPH-generating system consisting of 0.5 mM NADP⁺, 0.5 mM glucose-6-phosphate, 1 IU/mL glucose-6-phosphate dehydrogenase, 1 mg/mL diethylenetriaminepentaaceticacid (DETAPAC), and 3 mM MgCl₂ in a final incubation volume of 0.25 mL. Incubations were run for 0, 7, 15, 30, and 60 min with constant shaking at 37 °C in a water bath and were terminated by the addition of 0.75 mL cold ACN. After centrifugation at 3000 rpm for 5 min, the organic fraction was collected, the solvent was removed with a stream of argon and the residue was reconstituted in 125 μ L of MeOH and 125 μ L H₂O, mixed thoroughly, centrifuged at 13,000 rpm for 5 min and analyzed by high performance liquid chromatography. Samples were run on a Hitachi D-7000 HPLC system using a L-7100 analytical pump, L-7400 UV-Visible variable wavelength detector, and L-7600 automatic sample injector. A Gemini C18 column (250 x 4.6 mm, 5 μ m particle size; Phenomenex,) with a C18 guard column were used for chromatographic separation of the Mexiletine analogs. The mobile phase was an isocratic system using 75% water (0.05% TFA) and 25% acetonitrile (0.05% TFA) with a flow rate of 1.25 mL/min monitored at 275 nm. Disappearance of the analyte was monitored over time. A plot of the area under the curve for the normalized analyte versus time afforded the half-life values and k_{app} .




[0459] **Table 1. Metabolic Stability of 25, 70, 78 and 82 in Human, Dog, Mouse and Rat Liver microsomes.**


Compound	Liver Microsomes $t_{1/2}$ (min)			
	Human	Dog	Mouse	Rat
 70	104	184	59	52
 78	Stable > 95 % parent after 60 min	116	Stable > 95 % parent after 60 min	Stable > 95 % parent after 60 min
 25	141	Stable > 95 % parent after 60 min	208	475

 82	Stable > 95 % parent after 60 min	Stable > 95 % parent after 60 min	196	198
--	---	---	-----	-----

[0460] The Mexiletine analogs tested (**Table 1**, above) showed surprising stability in the presence of microsomes that efficiently metabolized testosterone. This is attributed to replacement of the metabolically labile 2,6-dimethyl groups of Mexiletine with metabolically stable CF₃- or H-moieties. Unexpectedly, movement of the dimethyl group to the 3,5-position also resulted in a compound that was relatively stable showing the microsomal oxidase(s) that oxidize Mexiletine at the 2,6-dimethyl positions do not efficiently oxidize analogs with substitutions at the 3,5-position. Moving the substituents from the 2,6-positions to the 3,5-positions improves planarity and decreases metabolism. Molecular energy minimization (Avogadro software) of Mexiletine and analogs showed the key dihedral angle of Mexiletine (20.7°) and showed lack of planarity due to an aryl 2,6-dimethyl “gem dimethyl” effect. In contrast, 3- or 5- or 3,5-disubstituted compounds showed a 0° dihedral angle. We hypothesize that 3, 5-aryl-mono or di-substituted Mexiletine analogs possess greater on-target potency and decreased arrhythmogenicity and decreased hepatic microsomal metabolism and better bioavailability.

Table 2. STABILITY OF LEAD COMPOUNDS IN S9 FRACTIONS





Compound	% Metabolism Human S9	% Metabolism Rat S9	% Metabolism Dog S9	% Metabolism Mouse S9
 78	41.1±28.9	2.1±1.4	25.6±17.9	11.6±3.0
 70	39.2±8.4	45.0±14.5	35.8±7.0	13.6±5.0
 25	7.0±0.1	97.8±19.5	98.0±28.1	34.6

 82	28.0±7.4	15.4±10.5	51.0±19.1	55.0±22.4
--	----------	-----------	-----------	-----------

[0461] Metabolism of Mexiletine analogs in the presence of hepatic S9 from rat, mouse, dog or human (0.5 mg of protein) were conducted as above and analyzed by HPLC as described above. With the possible exception of **25** (in the presence of rat or dog liver S9), the Mexiletine analogs were relatively stable in the presence of S9 (**Table 2**). Microsomes contain CYPs and FMO metabolic enzymes. S9 contains soluble enzymes (i.e., aldehyde oxidase, MAO, etc.). The data suggests that, unexpectedly, the presence of F-containing substituents decreases metabolism at distal sites due to metabolism by S9 enzymes.

[0462] **Stability of Mexiletine analogs at various temperatures and pH.** A typical incubation contained 100µM of the test compound prepared in PBS buffer (pH 7.4 or 3.0, 50 mM) with 1 % Ethanol. The test compounds were incubated at 37 °C. An aliquot from incubations was taken at various times and injected onto an RP-HPLC system as described above. Disappearance of the analyte was monitored over time. A plot of the area under the curve for the normalized analyte versus time afforded the half-life values and kapp.

[0463] **Table 3.** Chemical stability results for Mexiletine Analogs.

Compound	Half-Life @ pH 7.4 and 37 °C	Half-Life @ pH 3.0 and 37 °C
 70	stable > 30 days ^a	stable > 30 days ^a
 78	t _{1/2} = 30 days	stable > 30 days ^a
 25	stable > 30 day ^a	stable > 15 days ^a
 82	stable > 30 days ^a	stable > 15 days ^a

^aNo observed change in the parent peak compared to time zero by HPLC analysis.

[0464] Chemical stability of the Mexiletine analogs was apparent at pH 7.4 and pH 3 that mimicked the pH of serum and the contents of the gut, respectively (**Table 3**). The results showed no autooxidation, hydrolysis or other degradation is occurring and the compounds are remarkably stable for extended periods of time (> 30 days).

EXAMPLE 9: IN VIVO STUDIES WITH MEXILITENE ANALOGS

[0465] A prominent adverse reaction in the patient cohort (and others reported in the literature) administered (*R*)-Mexiletine is nausea and seizures. Because Mexiletine analogs (e.g., **25, 69, 70, 78, 82, 88, 105**) possessed LogP values (i.e., 3.2, 4.1, 3.7, 4.5, 2.3, 1.9 and 4.0, respectively) and total polar surface area (PSA Å² values of 35, 30, 35, 35, 35, 47 and 40, respectively) showing lipophilic and blood brain barrier-penetrating properties, we compared the behavioral properties of the compounds and compared them to Mexiletine. It is known that compounds with PSA less than 60 Å² and molecular weight below 450 (both observed for the Mexiletine analogs described herein) possess very good GI absorption properties and good CNS-absorption (to treat CNS diseases). Male BALBc mice (20-22 g) were used throughout these studies. The animals were maintained in a temperature-controlled room with 12-hr periods of light and darkness and had continuous access to water and animal food. Mexiletine or Mexiletine analogs showed good water solubility and were dissolved in 10:30:60 % DMSO:PEG400:water (v:v) and administered via i.p. injection (5 ml/kg). Groups contained 2-4 animals. Compound treatment was: vehicle or Mexiletine (30 or 100 or 200 mg/kg) or Mexiletine analogs (30 or 100 or 200 mg/kg) administered and monitored for 24 hr after treatment. HBRI compounds (**25, 36, 69, 70, 78, 82, 88** or **105**) possessed good solubility and were well-tolerated (30-100 mg/kg). For (*R*)- or (*S*)- or Racemic Mexiletine, administration of 30 mg/kg produced lethargy and in some cases immobilization. At greater doses (100 or 200 mg/kg), (*R*)- or Racemic Mexiletine produced seizures and death. (*S*)-Mexiletine (200 mg/kg) produced lethargy, immobilization and death but severe seizures were not observed. In contrast, mice treated with HBRI compounds **36, 69, 70, or 88** (200 mg/kg) only showed slight lethargy. All behavioral effects subsided after ~45 mins and animals recovered to full activity after 2-3 hours. Both Mexiletine analogs tested and Mexiletine (*R*- > Racemate > *S*-) produced apparent increase in fast heart rate effects that subsided with time. In conclusion, it was apparent that the Mexiletine analogs tested showed considerably less toxicity (i.e., lack of seizures and death) while preserving cardiovascular effects observed for Mexiletine. The lack of CNS and

peripheral (i.e., muscle) toxicity shows that the compounds have utility for CNS diseases such as seizures and epilepsy and other channelopathies.

EXAMPLE 10: ELECTROPHYSIOLOGY STUDIES WITH MEXILITENE ANALOGS

[0466] The basis for LQT3 is a mutation in SCN5a that encodes the voltage-gated Na channel responsible for cardiac action potential. The Na current (I_{Na}) has peak and late components: the peak component initiates the action potential but as voltage rises, the channel normally inactivates. The late current is normally a very small portion of the channels that do not inactivate. The LQT3 mutation impairs inactivation. The late component is then enlarged, resulting in action potential prolongation. We identified compounds that more potently and selectively blocked the late current (I_{NaL}) in LQT3 *patient-derived iPSC-cardiomyocytes*. Whole cell patch clamp electrophysiology experiments in LQTS3 cardiomyocytes helped determine the functional activity of drug candidates for inhibition of the late sodium current in the cells. Thus, we tested compounds for Peak (I_{NaP}) and Late (I_{NaL}) components. They were recorded in a “whole-cell” voltage-clamp mode configuration in response to voltage stimulation steps from -80 mV to +40 mV and their IC_{50} values determined (**Table 1**). **Table 1** is a summary table with the IC_{50} values for peak sodium current (I_{NaP}) inhibition, late sodium current (I_{NaL}) inhibition and the ratio of the IC_{50} for I_{NaP} inhibition to the IC_{50} for I_{NaL} inhibition. The Peak/Late ratio for **25**, **82**, **36** and **70** was 60 to 316-fold. This value is similar or greater to that observed measuring the effect on Na ion channels overexpressed in CHO cells (overexpressed $Na_v1.5$ encoded by the LQT3 mutated SCN5A) as presented in Table 1, **Example 2**, above. Mexiletine has a Peak/Late ratio of ~3. Thus, based on electrophysiology results, our approach of using patient-specific cells has succeeded quite well in producing drug candidates that are much more selective for I_{NaL} .

[0467] **Table 1. Effect of Mexiletine Analogs on Electrophysiology in Transfected CHO Cells.**

Compound	IC_{50} for I_{NaP} (μ M)	IC_{50} for I_{NaL} (μ M)	Ratio I_{NaP}/I_{NaL}	Ratio Mex ^a $I_{NaL}/Lead I_{NaL}$	Ratio of Mex Ratio/ Lead Ratio ^b
Mexiletine	145	51	2.7	N/A	N/A
25	102	1.7	60	30	22.3
82	200	1.8	111	28.3	41
36	51.8	0.38	136	134.2	50

70	171	0.54	316	94.4	117
-----------	-----	------	-----	------	-----

[0468] The peak current (I_{NaP}) mediates cardiac excitability and is an undesired effect of the molecules. Potency at the late current (I_{NaL}) is the desired goal. The ratio of the two indicates the selectivity and the IC_{50} indicates the potency of the molecules. Drug candidate (e.g., **36**) is as much as 134-fold more potent than racemic mexiletine. Compound **70** is as much as 117-fold more selective than mexiletine. Both metrics show that we have developed significantly more potent and selective inhibitor of I_{NaL} that could be used for the treatment of LQT3 or other indications where I_{NaL} inhibition is the therapeutic target.

EXAMPLE 11: METABOLISM STUDIES WITH MEXILITENE ANALOG ENANTIOMERS

[0469] Racemic **25**, **82**, **70** and **78** possessed metabolic stability (in liver microsomes of $T_{1/2} > 60$ mins) and chemical stability ($T_{1/2} > 30$ days, pH 7.4, 37°C) (see Example 8). Using the HPLC method described in **Example 8**, testing metabolism of drug candidate enantiomers showed good metabolic stability. Metabolism of Mexiletine and drug candidates was conducted in human liver S-9 and microsomes, respectively. In good agreement with the literature, Mexiletine was not metabolized very extensively (**Table 1**). In the presence of S-9, **25**, **36** and **70** were detectably metabolized as judged by HPLC. Metabolism was stereoselective with the (*R*)-enantiomer metabolized greater than the (*S*)-enantiomer (**Table 1**). In the presence of human liver microsomes, compounds **82**, **70** and **36** were metabolized as judged by HPLC. In good agreement with S-9 studies (above) metabolism was stereoselective, with the (*R*)-enantiomer greater than the (*S*)-enantiomer (**Table 1**).

[0470] **Table 1.** Metabolic Stability of Mexiletine and Analogs with Human Liver Preparations

Compound #	Liver S-9 $T_{1/2}$	Liver Microsomes $T_{1/2}$
(<i>S</i>)- 82	>95% after 1 hr	365 minutes
(<i>R</i>)- 82	>95% after 1 hr	136 minutes
(<i>R</i>)- 25	408 minutes	>95% after 1 hr
(<i>S</i>)- 25	>95% after 1 hr	>95% after 1 hr
(<i>R</i>)- 70	1015 minutes	406 minutes
(<i>S</i>)- 70	>95% after 1 hr	>95% after 1 hr
(<i>S</i>)- 36	>95% after 1 hr	>95% after 1 hr

(<i>R</i>)- 36	187 minutes	175 minutes
(<i>R</i>)- 78	>95% after 1 hr	>95% after 1 hr
(<i>S</i>)- 78	1040 minutes	>95% after 1 hr
(<i>R</i>)-Mexiletine	>95% after 1 hr	>95% after 1 hr
(<i>S</i>)-Mexiletine	>95% after 1 hr	>95% after 1 hr

[0471] It is known that certain CYPs (i.e., CYP3A4 and CYP2D6) play a role in the metabolism of Mexiletine. Accordingly, we examined the metabolism of leads with highly purified CYPs with an HPLC method (**Example 8**). As shown in **Table 2**, compared to Mexiletine, minor CYP-dependent metabolism was observed for **82** and **70**. The data show analogs **82**, **36** and **70** are more metabolically stable than Mexiletine in the presence of highly purified CYP 450. Unexpectedly, Mexiletine was metabolized by FMO (**Example 16**). It is known that FMO metabolizes primary amines but it was unknown that FMO metabolizes Mexiletine.

[0472] **Table 2.** Metabolic Stability of Mexiletine and Rac Compounds with Human Liver Cytochrome P-450a

	nmols metabolized	nmols/ μ g CYP	pmols product/ μ g CYP/min
Mexilitene			
CYP3A4	32.4	2.31	46.2
CYP3A5	34.2	2.44	48.8
CYP2D6	4.04	0.3	6.0
Rac 82			
CYP3A4	10.9	0.77	15.4
CYP3A5	29.9	2.13	42.6
CYP2D6	29.1	2.18	43.6
Rac 36			
CYP3A4	ND ^b		ND
CYP3A5	ND		ND
CYP2D6	ND		ND
Rac 70			
CYP3A4	ND		ND
CYP3A5	ND		ND
CYP2D6	4.6	.345	6.92

^a50 min incubation, ND, ^bNot Detectable

EXAMPLE 12: BEHAVIORAL AND SAFETY STUDIES WITH MEXILITENE ANALOG ENANTIOMERS

[0473] Safety has been established in several enantiomers of drug candidates. The literature states the LD₅₀ for Mexiletine in mice is 114 mg/kg. Administration of 200 mg/kg for **25**, **82**, **70**, or **36** enantiomers did not show any lethality. Thus, the LD₅₀ is >200 mg/kg for these compounds. In contrast, lethality was observed for Mexiletine at 100 and 200 mg/kg. Thus, the drug candidates examined are safer than Mexiletine.

[0474] A prominent adverse reaction in the patient cohort (and others reported in the literature) administered (*R*)-Mexiletine is nausea and seizures. We compared the behavioral properties of enantiomerically pure drug candidates (i.e., **25**, **82**, **70**, **78** and **36**) and compared them to (*R*)- or (*S*)-Mexiletine at 100 mg/kg (**Table 1**). Drug candidate enantiomers (i.e., enantiomers of **25**, **82**, **70**, **78** and **36**) were well-tolerated in vivo (100 mg/kg) in terms of behavioral effects (or lack thereof). In contrast, for (*R*)-Mexiletine, administration of 100 mg/kg produced immobilization, seizures and death. (*S*)-Mexiletine (100 mg/kg) produced lethargy and immobilization but severe seizures were not observed. In contrast, mice treated with drug candidate enantiomer (*R*)-**82**, **70**, or **78** (100 mg/kg) unexpectedly showed no apparent behavioral effects. Minor lethargy was observed for (*S*)-**25**, **82**, **70** and **78**. Thus, adverse behavioral effects were stereoselective (adverse effects *S*- > *R*-). In conclusion, compared to Mexiletine, it was apparent that (*R*)-enantiomer drug candidate compounds examined showed considerably less toxicity (i.e., seizures and death) than that observed for Mexiletine enantiomers.






Table 1. Effect of Stereochemistry on Behavioral Effects of Mexiletine Analogs.

Compound	Behavior Effect ^a (<i>R</i>)-enantiomer	Behavior Effect ^a (<i>S</i>)-enantiomer
82	No detectable effect	2/4 slightly lethargic
70	No detectable effect	2/4 lethargic
78	No detectable effect	2/4 shaking
36	3/4 immobilized	No detectable effect
25	4/4 immobilized	3/4 immobilized
Mexilitene	1 seizure, 1 death, 2 immobilized	4/4 immobilized




EXAMPLE 13: EFFECT OF PYRIDYL-MEXILETINE DERIVATIVES ON WT AND LQT-3 CARDIOMYOCYTES.














[0475] Pyridyl-Mexiletines moderate potency for LQT-3 shortening. Two most effective compounds, (i.e., unsubstituted 4-pyridyl (i.e., **126**) and ortho-methyl-3-pyridyl compounds (i.e., **111**), showed shortening EC₅₀ values of approximately 4 and 8 μ M, respectively. The unsubstituted 3-pyridyl derivative (i.e., **121**) with the N-methoxy ethyl modification also showed moderate shortening in LQT-3 cells (**Table 1**).

[0476] **Table 1.** Effect of Pyridyl-Mexiletine derivatives on WT and LQT-3 Cardiomyocytes.


Compound Number	Structure	WT-EC ₅₀ (μ M) Prolongation	WT-Cessation Dose (μ M)	LQT-EC ₅₀ (μ M) Shortening	LQT-Fold Shortening	LQT-Shortening Dose (μ M)
19		Does Not Prolong AP	133	1.38	1.406	66
20		Does Not Prolong AP	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
48		Does Not Prolong AP	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
94		18.48	No cessation of beating	12.82	1.287	66
96		Does Not Prolong AP	No cessation of beating	20.7	1.358	133



[0477] **Table 2.** Effect of 3-Pyridyl-Mexiletine derivatives on WT and LQT-3 Cardiomyocytes

Compound Number	Structure	WT-EC ₅₀ (μ M) Prolongation	WT-Cessation Dose (μ M)	LQT-EC ₅₀ (μ M) Shortening	LQT-Fold Shortening	LQT-Shortening Dose (μ M)
110		33.76	No cessation of beating	62.56 (Prolongation and EADs)	1.546 (Prolongation)	133
111		Does Not Prolong AP	133	8.57	1.426	Does Not Shorten
112		19.4	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten

113		7.24	200	Does Not Shorten	Does Not Shorten	Does Not Shorten
114		Does Not Prolong AP	No cessation of beating	67.5	1.233	22
115		25.7	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
116		Does Not Prolong AP	200	Shortens	1.422	22
117		Does Not Prolong AP	66	Does Not Shorten	Does Not Shorten	Does Not Shorten
118		8.22	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
119		Does Not Prolong AP	No cessation of beating	Shortens	1.123	22
120		7.33	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
121		25.42	No cessation of beating	2.58	1.144	22
122		Does Not Prolong AP	200	46.57	1.188	66
123		Does Not Prolong AP	200	Shortens	1.402	66
124		Does Not Prolong AP	66	Shortens	1.601	7.4
125		Does Not Prolong AP	66	Does Not Shorten	Does Not Shorten	Does Not Shorten

[0478] Table 3. Effect of 4-Pyridyl-Mexiletine derivatives on WT and LQT-3 Cardiomyocytes




Compound Number	Structure	WT-EC ₅₀ (μM) Prolongation	WT-Cessation Dose (μM)	LQT-EC ₅₀ (μM) Shortening	LQT-Fold Shortening	LQT-Shortening Dose (μM)
126		Does Not Prolong AP	No cessation of beating	3.82	1.281	7.4





127		97.68	No cessation of beating	Does Not Shorten	Does Not Shorten	Does Not Shorten
128		Does Not Prolong AP	No cessation of beating	Shortens	1.226	22

EXAMPLE 14: NAPHTHALENE DERIVATIVES OF MEXILETINE AND ANALOGS.

[0479] Naphthalene derivatives of Mexiletine and several lead compounds bearing phenol substitution were synthesized following the previously described method (**Scheme 1, Example 3**) and obtained in good yield and excellent purity. Naphthalene analogs of Mexiletine and the lead compounds showed potency with significant LQT-3 shortening. Although the shortening EC_{50} was generally greater than the corresponding phenyl analogs, the cessation dose was also increased. The most potent bicyclic compound tested contained 1-naphthol as a phenol moiety analog, consistent with the hypothesis that this would be highly potent given the structural similarity to analogs with 2,3-dimethyl phenol substituents (e.g., **30-36**). Although showing some prolongation effects in wild type cells, the mono-trifluoromethyl naphtha-Mexiletine compound (i.e., **134**) was highly potent and did not induce cessation of beating at the concentrations examined.

[0480] **Table 1.** Effect of Naphtha-Mexiletine derivatives on WT and LQT-3 Cardiomyocytes.

Compound Number	Structure	WT- EC_{50} (μ M) Prolongation	LQT- EC_{50} (μ M) Shortening	LQT-Cessation Dose (μ M)	LQT-Fold Shortening	LQT-Shortening Dose (μ M)
129		Does Not Prolong AP	0.82	66	1.316	2.5
130		Does Not Prolong AP	8.7	133	1.459	66
131		Does Not Prolong AP	4.73	133	1.309	22

132		Does Not Prolong AP	Shortens	No cessation of beating	1.205	133
133		Does Not Prolong AP	8.83	133	1.302	22
134		24.40	1.79	No cessation of beating	1.515	133
135		Does Not Prolong AP	Shortens	200	1.667	133

EXAMPLE 15: METABOLISM OF DEUTERATED MEXILETINE ANALOGS.

[0481] As discussed above (**Example 6**), deuterated Mexiletine analogs were synthesized and tested in hepatic preparations or enzymes to determine if deuteration would decrease metabolism compared to Mexiletine. Compared to Mexiletine, data of **Table 1**, below, shows that the deuterated analogs were in general, more metabolically stable. In many cases, an apparent large isotope effect is apparent for the deuterated compounds compared to non-deuterated Mexiletine.

[0482] **Table 1.** Effect of Metabolism on Deuterated Analogs and unlabeled Mexiletine.

Compound	Mouse liver S-9 (nmol/incub) ^a	Human FMO1 (nmol/incub) ^b	Human FMO3 (nmol/incub) ^b	Human CYP3A4 (nmol/incub) ^c
Mexiletine	5.2	6.7	ND ^d	3.0
104a	ND ^d	0.8	0.6	1.1
104c	13.2	1.4	1.3	1.0
104d	ND	0.3	0.7	0.3
104b	ND	1.0	0.05	0.3

[0483] ^a0.4 mg protein/incubation; ^b15 µg enzyme/incubation; ^c3 pmol enzyme/incubation; ^dND, no detectable decrease. Incubations were run for 30 mins with shaking at 37 °C. Expressed as nmol metabolism/incubation.

[0484] As a further example, the metabolism of Mexiletine was compared to deuterated Mexiletine (**135**) and Phenyl Mexiletine was compared with deuterated Phenyl Mexiletine (**136**), (compounds in **Example 3**). As shown in **Table 2**, generally, compounds with deuterium (i.e., **135** and **136**) showed large and unexpected isotope effects on metabolism. This will translate to a large isotope effect on in vivo metabolism, a decrease in clearance, greater

bioavailability and longer efficacy. This will result in a more long-lived human drug resulting in fewer doses/day and less side effects and greater efficacy.

Table 2. Effect of Metabolism on Deuterated Mexiletine and Phenyl Mexiletine.

Condition	Mexiletine	D ^d -Mexiletine	Phenyl Mexiletine	D ^d -Phenyl Mexiletine
	nmol metab./incub.	nmol metab./incub.	nmol metab./incub.	nmol metab./incub.
Mouse S-9 ^a	8.0	3.9	2.5	1.4
Human S-9 ^a	3.9	2.7	1.2	1.4
Human FMO1 ^b	2.4	1.4	0.33	0.06
Human CYP3A4 ^c	4.1	5.2	2.3	1.5


^a0.4 mg protein/incubation; ^b15 µg enzyme/incubation; ^c3 pmol enzyme/incubation; Incubations were run for 30 mins with shaking at 37 °C and results are in nmol of metabolism/incubation, ^dD stands for deuterium.

EXAMPLE 16. EFFECT OF (*R*)-82 ON AN AGED RAT HEART PERFUSION MODEL OF ARRHYTHMIA.

[0485] Conduction velocity (CV), action potential duration (APD) and responsiveness to drugs was measured in ex-vivo rat heart preparations (**Figure 1**). We chose a rat heart model to test for the effect of (*R*)-82 (i.e., (*R*)-Dd, **Example 4**) to decrease arrhythmias because CV and APD are preserved in buffer-perfused rat hearts up to 2 days. In contrast, in this model, continuous presence (perfusion) of H₂O₂ (0.1 mM) produces early after depolarizations (EADs) and ectopic ventricular beats 6 min after exposure that degenerates to ventricular tachycardia (VT) and ventricular fibrillation (VF) after 12 min (**Figure 1**). Left untreated, the heart would die within 45 mins. Using this preparation, complete resolution of all forms of arrhythmias to normal sinus rhythm was observed 30 min after perfusion of compound (*R*)-82 (10 µM) in the continuous presence of H₂O₂ (0.1 mM) (**Figure 2**). This shows that administration of (*R*)-82 (i.e., (*R*)-Dd, **Example 4**) to a heart suffering from severe arrhythmias potently reverses VT and VF and corrects EADs in a very clinically relevant short time. The effect of (*R*)-82 is similar to or more potent than the effect of ranolazine (10 µM) in the same ex vivo model. The conclusion is that (*R*)-82 is more efficacious than the currently used standard of care.

Claims

1. A compound of Formula I:



or a salt thereof, wherein:

A, B, D are Carbon;

R₁ is selected from the group consisting of methyl, trideuteromethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₆-C₂₄)aryl, and (C₅-C₂₄)heteroaryl, wherein (C₆-C₂₄)aryl and (C₅-C₂₄)heteroaryl are optionally substituted with 1 or 2 R₈ substituents independently selected from the group consisting of fluoro, chloro, trideuteromethyl, and trifluoromethyl, or with 1 to 5 R₈ substituents, wherein each R₈ is deuterium;

R₁' is deuterium;

R₂ is hydrogen;

R₃ is selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl;


R₄ is selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl;

R₅ is selected from the group consisting of hydrogen, deuterium, halo, methyl, trideuteromethyl, and trifluoromethyl;

R₆ and R₇ are independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl; and

wherein the indicated (*) carbon atom is in the *R*- or *S*-configuration.

2. The compound of claim 1 wherein the compound is of Formula Ia:



or a salt thereof, wherein:

R₁ is selected from the group consisting of methyl, phenyl, and naphthyl;


R₁' is deuterium;

R₂ is hydrogen; and

R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen, methyl and trifluoromethyl, or each of R₃, R₄, R₅ and R₆ is deuterium.


3. The compound of claim 1 or 2, wherein R₁ is methyl and the indicated (*) carbon atom is in the *S*-configuration.

4. The compound of claim 3, wherein the compound is:




or a salt thereof.

5. A compound wherein the compound is:



or a salt thereof, or


wherein the compound is:



or a salt thereof.

6. The compound of claim 5 wherein the indicated (*) carbon atom is in the *R*-configuration.

7. A compound of Formula II:



or a salt thereof, wherein:

A, B, D are Carbon;

R₁ is selected from the group consisting of hydrogen, deuterium, methyl, trideuteromethyl, (C₂-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₆-C₂₄)aryl, and (C₅-C₂₄)heteroaryl, wherein (C₆-C₂₄)aryl and (C₆-C₂₄)heteroaryl are optionally substituted with 1 to 2 R₈ substituents wherein each R₈ is independently selected from the group consisting of fluoro, chloro, methyl, trideuteromethyl, trifluoromethyl, or with 1 to 5 R₈ substituents, wherein each R₈ is deuterium;

R₁' is selected from the group consisting of hydrogen and deuterium;

R₂ is selected from the group consisting of hydrogen, methyl, trideuteromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, (C₂-C₆)alkyl, and (C₃-C₆)cycloalkyl;

R₃ is selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl;


R₄ is selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl;

R₅ is selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl;

R₆ and R₇ are independently selected from the group consisting of hydrogen, deuterium, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl; and


wherein the indicated (*) carbon atom is in the *R*- or *S*-configuration, provided that both R₁ and R₁' are not hydrogen or deuterium.

8. The compound of claim 7 wherein the compound is of Formula IIa:



or a salt thereof.


9. The compound of claim 8 wherein the compound is of Formula IIb:



or a salt thereof, wherein:


one or two of R₈ are independently selected from the group consisting of hydrogen, fluoro, chloro, methyl, trideuteromethyl, and trifluoromethyl and the other R₈ are hydrogen, or each of R₈ is deuterium.

10. The compound of claim 9 wherein the compound is:




or a salt thereof.

11. The compound of claim 9 wherein the compound is:



or a salt thereof.

12. The compound of claim 9 wherein the compound is:



or a salt thereof.

13. The compound of any one of claims 7-12 wherein the indicated (*) carbon atom is in the *R*-configuration.

14. The compound of any one of claims 7-12 wherein R₁' is deuterium.

15. The compound of any one of claims 7-12 wherein R₁' is deuterium and the indicated (*) carbon atom is in the *R*-configuration.

16. The compound of any one of claims 1-15 wherein the compound salt is that of a pharmaceutically acceptable salt wherein the pharmaceutically acceptable salt is an acid addition salt from hydrochloric, hydrobromic, phosphoric, phosphonic, nitric, sulfuric, acetic, chloroacetic, dichloroacetic, trichloroacetic, trifluoroacetic, oxalic, maleic, mandelic, malonic, citric, tartaric, fumaric, salicylic, methanesulfonic, benzenesulfonic, toluenesulfonic, or 2,6-dimethylbenzenesulfonic acid.

17. A composition comprising a compound of any one of claims 1-15 and one, two, or three compounds independently selected from the group consisting of anesthetics, anti-arrhythmics, anticonvulsants, anti-antiarrhythmic peptides, anti-antiarrhythmic growth factors, anti-antiarrhythmic proteins, anti-antiarrhythmic drug-peptide conjugates, antibody-drug conjugates, vitamins, and nutraceuticals.

18. A drug delivery system comprised of a compound of any one of claims 1-15 and a component selected from the group consisting of pharmaceutically accepted polymers, collagen, modified collagens, thrombin-collagen gels, starches, modified starches, gels, hydrogels, pastes, colloids, suspensions, encapsulants, cyclodextrins, micelles, vesicles, and liposomes.

19. A composition comprising a compound of any one of claims 1-15 and isolated cells capable of acting on functional muscle cells, neuronal cells or cells of the central nervous system.

20. The composition of claim 20 wherein the cells are progenitor cells or stem cells of induced, embryonic or adult origin.

21. A method of inhibiting sodium channels in isolated tissue cells comprising the step of contacting said cells with an effective amount of a compound of any one of claims 1-15.

22. Use of a compound of any one of claims 1-15 in preparation of a medicament for the inhibition of sodium channels in cells of an organism.

23. The use according to claim 22 wherein said inhibition of said sodium channels modulates membrane potential, action potential or physiological function of the cells of the organism, wherein the cells of the organism are those of heart, brain, muscle, central nervous system, or are peripheral cells.

24. The use according to claim 23, wherein the heart, brain, muscle, central nervous system, or peripheral cells are mature cells or progenitor cells.

25. The use according to claim 24 wherein the progenitor cells are stem cells of induced, embryonic or adult origin.

26. Use of a compound of any one of claims 1-15 and an anti-arrhythmic drug in preparation of a medicament for inhibiting sodium channels in mammalian cells.

27. The use according to claim 26, wherein the anti-arrhythmic drug is an ion channel inhibitor or agonist.

28. The use according to claim 27 wherein the anti-arrhythmic drug is a Class 1, Class 2, Class 3, Class 4 or Class 5 anti-arrhythmic drug.

29. Use of a compound of any one of claims 1-15 in preparation of a medicament for inducing anesthetic, anti-arrhythmic, anticonvulsant or anti-hyperexcitability therapeutic effects in a subject in need thereof.

30. Use of a compound of any one of claims 1-15 in contacting isolated progenitor cells or stem cells of induced, embryonic cells or adult origin cells for inducing anesthetic, anti-arrhythmic, anticonvulsant, or anti-hyperexcitability therapeutic effects in a subject in need thereof.

31. A compound of any one of claims 1-15 for therapeutic modulation of a channelopathy or inducing anesthesia in a subject.

32. The compound of claim 31 wherein the channelopathy is a cardiac arrhythmia or amyotrophic lateral sclerosis or seizures.






FIGURE 1

*FIGURE 2*



(I)